[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1339
11. Sarosi GA Jr: Introduction: esophagus, dysplasia, and early esophageal adenocarcinoma: managing the transition. J Gastrointest Surg; 2010 Jun;14(6):935-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Introduction: esophagus, dysplasia, and early esophageal adenocarcinoma: managing the transition.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Esophagus / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):788-97 [18341497.001]
  • [Cites] Cancer Lett. 2009 Mar 18;275(2):170-7 [18703277.001]
  • [Cites] JAMA. 2002 Apr 17;287(15):1972-81 [11960540.001]
  • [Cites] Int J Cancer. 2008 Sep 15;123(6):1422-8 [18546259.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • (PMID = 20162375.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Introductory Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Bhat MA, Naikoo ZA, Dass TA, Lone RA, Dar AM: Role of intraoperative sentinel lymph node mapping in the management of carcinoma of the esophagus. Saudi J Gastroenterol; 2010 Jul-Sep;16(3):168-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of intraoperative sentinel lymph node mapping in the management of carcinoma of the esophagus.
  • BACKGROUND/AIM: Precise evaluation of lymph node status is one of the most important factors in determining clinical outcome in treating gastro-intestinal (GI) cancer.
  • Sentinel lymph node (SLN) mapping clearly has become highly feasible and accurate in staging GI cancer.
  • This study aims to investigate the feasibility and accuracy of detection of SLN using methylene blue dye in patients with carcinoma of the esophagus and assess its potential role in determining the rational extent of lymphadenectomy in esophageal cancer surgery.
  • MATERIALS AND METHODS: Thirty-two patients of esophageal cancer diagnosed on endoscopic biopsy were enrolled in this prospective study.
  • The SLNs of esophageal cancer were only found in N1 area in 21 (80.77%) cases, and in N2 or N3 area in only 19.33%.
  • SLN had a sensitivity of 85.71% in mid esophageal tumors and 93.33% in lower esophageal tumors.
  • The SLN biopsy had sensitivity of 87.5% in the case of squamous cell carcinoma and 92.86% in the cases of adenocarcinoma of the esophagus.
  • The accuracy of the procedure for squamous cell carcinoma and adenocarcinoma was 60% and 76.47%, respectively.
  • CONCLUSION: SLN mapping is an accurate diagnostic procedure for detecting lymph node metastasis in patients with esophageal cancer and may indicate rational extent of lymphadenectomy in these patients.
  • SLN mapping provides "right nodes" to the pathologists for detailed analysis and appropriate staging, thereby helping in individualizing the multi-modal treatment for esophageal cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Sentinel Lymph Node Biopsy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. METHYLENE BLUE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Treat Res. 2005;127:123-39 [16209080.001]
  • [Cites] Surg Clin North Am. 2000 Dec;80(6):1799-809 [11140874.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):293-304 [12424851.001]
  • [Cites] J Am Coll Surg. 2003 Jan;196(1):68-74 [12517553.001]
  • [Cites] Br J Surg. 2003 Feb;90(2):178-82 [12555293.001]
  • [Cites] Am J Surg. 2004 Feb;187(2):270-3 [14769318.001]
  • [Cites] Ann Surg Oncol. 2004 Mar;11(3 Suppl):245S-9S [15023761.001]
  • [Cites] Ann Surg Oncol. 2004 Mar;11(3 Suppl):255S-8S [15023763.001]
  • [Cites] J Surg Oncol. 2004 Jul 15;87(1):32-8 [15221917.001]
  • [Cites] Cancer. 1977 Feb;39(2):456-66 [837331.001]
  • [Cites] Gut. 1992 Jan;33(1):11-5 [1740265.001]
  • [Cites] Arch Surg. 1992 Apr;127(4):392-9 [1558490.001]
  • [Cites] Ann Surg. 1994 Sep;220(3):391-8; discussion 398-401 [8092905.001]
  • [Cites] World J Surg. 1997 Oct;21(8):822-31 [9327673.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):482-6 [10215818.001]
  • [Cites] Ann Surg. 1955 Sep;142(3):486-506 [13249345.001]
  • [Cites] Br J Surg. 2005 Jan;92(1):60-7 [15584066.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 2005 May 1;43(9):569-72 [15938926.001]
  • [Cites] Cancer Metastasis Rev. 2006 Jun;25(2):269-77 [16770539.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(5):893-906 [16997168.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):80-7 [18004627.001]
  • [Cites] Ann Thorac Surg. 2008 Feb;85(2):S751-6 [18222210.001]
  • [Cites] Ned Tijdschr Geneeskd. 2008 Jan 5;152(1):38-45 [18240761.001]
  • [Cites] Eur J Cardiothorac Surg. 2008 Aug;34(2):427-31 [18502142.001]
  • [Cites] Surg Endosc. 2008 Dec;22(12):2753-60 [18813994.001]
  • [Cites] Pathol Oncol Res. 1999;5(4):291-6 [10607924.001]
  • [Cites] Cancer. 2000 Nov 1;89(9):1869-73 [11064342.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Apr;17(4):374-81 [11982715.001]
  • (PMID = 20616411.001).
  • [ISSN] 1998-4049
  • [Journal-full-title] Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
  • [ISO-abbreviation] Saudi J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; T42P99266K / Methylene Blue
  • [Other-IDs] NLM/ PMC3003219
  •  go-up   go-down


13. Gockel I, Sultanov FS, Domeyer M, Trinh TT, Gönner U, Junginger T: [Surgical therapy for esophageal carcinoma: a prospective 20-year analysis]. Zentralbl Chir; 2008 Jun;133(3):260-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical therapy for esophageal carcinoma: a prospective 20-year analysis].
  • [Transliterated title] Chirurgische Therapie des Osophaguskarzinoms: Eine prospektive 20-Jahres-Analyse.
  • BACKGROUND: The aim of our study was the analysis of long-term developments in the surgical therapy for esophageal carcinoma at our hospital over a period of 20 years with a differentiated view on the two predominant histological tumour types.
  • PATIENTS AND METHODS: Between September 1985 and September 2005, esophageal resections were performed in 470 patients at our clinic on account of a malignant tumour of the esophagus.
  • The abdomino-thoracic resection with abdominal and extended mediastinal lymph node dissection as well as intrathoracic anastomosis was the standard treatment in the case of squamous cell carcinoma, whereas in adenocarcinoma a transhiatal resection with abdominal and dorsal mediastinal lymphadenectomy and cervical esophagogastrostomy was carried out.
  • A proportionally identical amount of transhiatal resections for squamous cell carcinoma was found in both intervals, whereas the transhiatal procedures for adenocarcinoma increased in the last decade (3.6 % in the period between 9 / 1985 and 9 / 1995, as compared with 23.6 % between 10 / 1995 and 9 / 2005) (p < 0.05).
  • While the overall prognosis for squamous cell carcinoma did not significantly differ in the two decades (p = 0.2040), patients with adenocarcinoma were found to have a significantly improved long-term survival (log-rank test: p = 0.0365) in the second decade.
  • The prognosis for adenocarcinoma, therefore, could be improved in the course of time with a 3-year survival rate of finally 40 % (as compared with 17.5 % in the first decade), and a 5-year survival rate of 25 % (as compared with 15 %).
  • CONCLUSION: Surgical therapy for esophageal carcinoma has undergone distinct changes over the past 20 years.
  • Especially with adenocarcinoma of the esophagus, these changes have led to a significantly more favourable long-term prognosis.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Diffusion of Innovation. Esophageal Neoplasms / surgery. Thoracotomy / trends
  • [MeSH-minor] Adult. Aged. Anastomosis, Surgical. Diaphragm / surgery. Disease-Free Survival. Esophagus / surgery. Female. Follow-Up Studies. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Stomach / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18563693.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


1
Advertisement
4. Haghdoost AA, Hosseini H, Chamani G, Zarei MR, Rad M, Hashemipoor M, Zahedi MJ, Darvish-Moghadam S: Rising incidence of adenocarcinoma of the esophagus in Kerman, Iran. Arch Iran Med; 2008 Jul;11(4):364-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rising incidence of adenocarcinoma of the esophagus in Kerman, Iran.
  • BACKGROUND: The fall in the incidence of esophageal squamous cell cancer and noncardia gastric cancers in western countries parallels a concomitant rise in the incidence of gastric cardia cancer and distal adenocarcinoma of the esophagus.
  • We aimed to investigate the incidence trend of different gastric and esophageal cancers in Kerman, southeast Iran.
  • METHODS: The information of all newly diagnosed patients with gastric and esophageal cancers were collected actively from all histopathology departments around the Kerman Province during 1991 - 2002 retrospectively.
  • RESULTS: The annual age standardized incidence risks of esophageal and gastric cancers in Kerman were 1.9 and 6.9 per 100,000 populations.
  • In average, the risks of gastric and esophageal squamous cell cancers were more or less constant, while the risk of adenocarcinoma of the esophagus increased around 11% annually.
  • The rising incidence of adenocarcinoma of the esophagus in Kerman parallels its temporal pattern in western countries.
  • [MeSH-major] Adenocarcinoma / epidemiology. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18588366.001).
  • [ISSN] 1029-2977
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Iran
  •  go-up   go-down


15. Madani K, Zhao R, Lim HJ, Casson SM, Casson AG: Obesity is not associated with adverse outcome following surgical resection of oesophageal adenocarcinoma. Eur J Cardiothorac Surg; 2010 Nov;38(5):604-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obesity is not associated with adverse outcome following surgical resection of oesophageal adenocarcinoma.
  • OBJECTIVE: To study the impact of obesity on postoperative morbidity and outcome following surgical resection of primary oesophageal adenocarcinoma (EADC).
  • DFS and OS at 5 years were increased for patients who were obese at the time of oesophageal resection (P=0.008).
  • CONCLUSIONS: Obesity is not associated with increased postoperative complication rates or adverse outcome following oesophageal resection, and should therefore not be considered a relative contraindication to the surgical management of EADC.
  • The improved survival of obese patients who underwent oesophageal resection for EADC suggests that further investigation of the association between obesity and oesophageal malignancy is now warranted.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagectomy / adverse effects. Obesity / complications

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • [ErratumIn] Eur J Cardiothorac Surg. 2010 Dec;38(6):820-1
  • (PMID = 20444616.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


16. Islami F, Kamangar F: Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res (Phila); 2008 Oct;1(5):329-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter pylori and esophageal cancer risk: a meta-analysis.
  • We conducted this meta-analysis to examine the association between Helicobacter pylori and esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma.
  • Case-control or nested case-control studies were selected if they used serology or endoscopic methods to detect H. pylori in the stomach and if control subjects were not restricted to upper gastrointestinal tract cancer or peptic ulcer disease patients.
  • For esophageal squamous cell carcinoma, the summary OR (95% CI) was 1.10 (0.78-1.55).
  • [MeSH-major] Adenocarcinoma / etiology. Carcinoma, Squamous Cell / etiology. Esophageal Neoplasms / etiology. Helicobacter Infections / epidemiology. Helicobacter pylori / physiology

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1998 Feb 15;58(4):588-90 [9485003.001]
  • [Cites] Am J Gastroenterol. 1998 Apr;93(4):542-6 [9576445.001]
  • [Cites] Gastroenterology. 1998 Jul;115(1):50-7 [9649458.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Arch Surg. 1999 Jul;134(7):722-6 [10401822.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):520-4 [10404065.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):456-63 [15455378.001]
  • [Cites] Am J Gastroenterol. 2004 Dec;99(12):2297-301 [15571572.001]
  • [Cites] J Infect Dis. 2005 Mar 1;191(5):761-7 [15688293.001]
  • [Cites] Sci Am. 2005 Feb;292(2):38-45 [15715390.001]
  • [Cites] Am J Gastroenterol. 2005 Mar;100(3):588-93 [15743356.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1754-61 [16030113.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • [Cites] EMBO Rep. 2006 Oct;7(10):956-60 [17016449.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 18;98(20):1445-52 [17047193.001]
  • [Cites] Arch Intern Med. 2007 Apr 23;167(8):821-7 [17452546.001]
  • [Cites] Gastroenterology. 2007 May;132(6):2116-30 [17498507.001]
  • [Cites] J Infect Dis. 1993 Jul;168(1):219-21 [8515114.001]
  • [Cites] Am J Epidemiol. 1994 Nov 1;140(9):771-8 [7977286.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Mar;4(2):85-92 [7742727.001]
  • [Cites] Biometrics. 1994 Dec;50(4):1088-101 [7786990.001]
  • [Cites] Dis Esophagus. 1997 Jul;10(3):196-200 [9280079.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] Am J Surg Pathol. 1997 Sep;21(9):1023-9 [9298878.001]
  • [Cites] Am J Gastroenterol. 2007 Jun;102(6):1166-72 [17378911.001]
  • [Cites] Am J Epidemiol. 2007 Jun 15;165(12):1424-33 [17420181.001]
  • [Cites] Cancer Causes Control. 2007 Sep;18(7):713-22 [17562192.001]
  • [Cites] Scand J Gastroenterol. 2007 Aug;42(8):933-40 [17613922.001]
  • [Cites] Am J Gastroenterol. 2007 Aug;102(8):1603-9 [17488251.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Dec;5(12):1413-7, 1417.e1-2 [17997357.001]
  • [Cites] Gut. 2008 Feb;57(2):173-80 [17932103.001]
  • [Cites] Gut. 2008 Mar;57(3):298-305 [17965056.001]
  • [Cites] Br J Cancer. 2008 Feb 26;98(4):689-92 [18253117.001]
  • [Cites] Gut. 2008 May;57(5):561-7 [18194986.001]
  • [Cites] Gut. 2008 Jun;57(6):734-9 [18025067.001]
  • [Cites] J Infect Dis. 2008 Aug 15;198(4):553-60 [18598192.001]
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):387-94 [10685740.001]
  • [Cites] Aust N Z J Surg. 2000 Jan;70(1):26-33 [10696939.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):172-6 [17179990.001]
  • [Cites] BMC Cancer. 2006;6:287 [17173682.001]
  • [Cites] Cancer. 2007 Feb 15;109(4):668-74 [17211862.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1999 May;11(5):503-9 [10755253.001]
  • [Cites] J Infect Dis. 2000 Apr;181(4):1359-63 [10762567.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2520-8 [10861428.001]
  • [Cites] Digestion. 2000;62(4):225-31 [11070405.001]
  • [Cites] J Clin Invest. 2001 Apr;107(7):767-73 [11285290.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 20;93(12):937-41 [11416115.001]
  • [Cites] BMJ. 2001 Jul 14;323(7304):101-5 [11451790.001]
  • [Cites] Gut. 2001 Sep;49(3):347-53 [11511555.001]
  • [Cites] Am J Gastroenterol. 2001 Dec;96(12):3406-10 [11774957.001]
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1415-25 [11821356.001]
  • [Cites] Gut. 2002 Mar;50(3):295-8 [11839704.001]
  • [Cites] Helicobacter. 2001 Dec;6(4):310-6 [11843963.001]
  • [Cites] Lancet. 2002 Mar 16;359(9310):931-5 [11918912.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1375-80 [12094853.001]
  • [Cites] Gut. 2002 Sep;51(3):457-8 [12171977.001]
  • [Cites] N Engl J Med. 2002 Oct 10;347(15):1175-86 [12374879.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1095-9 [12376513.001]
  • [Cites] Int J Cancer. 2002 Dec 1;102(4):422-7 [12402314.001]
  • [Cites] Clin Diagn Lab Immunol. 2002 Nov;9(6):1313-7 [12414766.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):235-56 [12424848.001]
  • [Cites] J Natl Cancer Inst. 2002 Nov 20;94(22):1680-7 [12441323.001]
  • [Cites] Int J Cancer. 2003 Mar 1;103(6):815-21 [12516104.001]
  • [Cites] Science. 2003 Mar 7;299(5612):1582-5 [12624269.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1193-201 [12730860.001]
  • [Cites] BMJ. 2003 Sep 6;327(7414):557-60 [12958120.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(17):2487-94 [14602134.001]
  • [Cites] World J Gastroenterol. 2003 Nov;9(11):2501-4 [14606084.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1636-44 [14724815.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):388-96 [14996860.001]
  • [Cites] Br J Cancer. 2004 Apr 5;90(7):1402-6 [15054463.001]
  • [Cites] Nat Rev Cancer. 2004 Sep;4(9):688-94 [15343275.001]
  • [Cites] Lancet. 1984 Jun 16;1(8390):1311-5 [6145023.001]
  • [Cites] Mod Pathol. 1989 Sep;2(5):473-6 [2479007.001]
  • [Cites] J Natl Cancer Inst. 1991 Dec 4;83(23):1734-9 [1770552.001]
  • [Cites] Hum Pathol. 1997 Sep;28(9):1007-9 [9308723.001]
  • [Cites] BMJ. 1997 Sep 13;315(7109):629-34 [9310563.001]
  • [Cites] Oncology. 1998 Jan-Feb;55(1):16-9 [9428370.001]
  • [Cites] BMJ. 1998 Jan 10;316(7125):140-4 [9462324.001]
  • [CommentIn] Cancer Prev Res (Phila). 2008 Oct;1(5):308-11 [19138974.001]
  • [CommentIn] Cancer Prev Res (Phila). 2009 Jan;2(1):94 [19139023.001]
  • (PMID = 19138977.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / cagA protein, Helicobacter pylori
  • [Other-IDs] NLM/ NIHMS419215; NLM/ PMC3501739
  •  go-up   go-down


17. Wang RH, Ou-Yang Q, Chen X, Li GD, Xiang JY: [Chemoprevention of Barrett's esophagus by celecoxib in rats]. Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Sep;38(5):498-504
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemoprevention of Barrett's esophagus by celecoxib in rats].
  • OBJECTIVE: To examine the chemopreventive effect of selective cyclooxygenase-2 (COX-2) inhibitor celecoxib for Barrett's esophagus in rats.
  • METHODS: Fifty 8-week-old male Sprague Dawley rats underwent esophagojejunostomy to induce Barrett's esophagus model.
  • The degree of inflammation, Barrett's esophagus, adenocarcinoma, COX-2 expression and PGE(2) of animals were assessed.
  • The incidence of mild, moderate and severe degree esophageal inflammation in celecoxib group and control group was 14/19(73.68%), 4/19(21.05%), 1/19(5.26%); 4/17(23.53%), 5/17(29.41%), 8/17(47.06%)(P<0.05), respectively.
  • The incidence of Barrett's esophagus was 7/19(36.84%), 13/17(76.47%) in two group respectively(P<0.05); The incidence of Barrett's esophagus with dysplasia was 2/19(10.53%), 8/17(47.06%)(P<0.05), respectively.
  • No esophageal pathological changes were found in sham operation group.
  • CONCLUSION: Selective COX-2 inhibitors celecoxib can inhibit inflammations, development of Barrett's esophagus and esophagus adenocarcinoma.
  • [MeSH-major] Barrett Esophagus / prevention & control. Cyclooxygenase 2 Inhibitors / therapeutic use. Pyrazoles / therapeutic use. Sulfonamides / therapeutic use

  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19830863.001).
  • [ISSN] 1008-9292
  • [Journal-full-title] Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
  • [ISO-abbreviation] Zhejiang Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Pyrazoles; 0 / Sulfonamides; EC 1.14.99.1 / Cyclooxygenase 2; JCX84Q7J1L / Celecoxib; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


18. Souza RF: Molecular mechanisms of acid exposure in Barrett's esophagus. Inflammopharmacology; 2007 Jun;15(3):95-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular mechanisms of acid exposure in Barrett's esophagus.
  • Esophageal adenocarcinoma is one of the most deadly gastrointestinal tumors.
  • Gastroesophageal reflux has been established as a major risk factor for esophageal adenocarcinoma and Barrett's esophagus, the condition in which the normal squamous cells of the esophagus are replaced by metaplastic, specialized intestinal cells that are predisposed to malignancy.
  • Data from ex vivo and in vitro model systems suggests that acid exposure has pro-proliferative and anti-apoptotic effects which may facilitate neoplastic progression of Barrett's esophagus.
  • However, it is not clear whether the effects of acid exposure on proliferation and apoptosis are a direct result of the acid exposure itself, or whether they result indirectly from the effects of acid on inducing esophageal inflammation.
  • Such distinction may help in optimizing the level of gastric acid suppression for the prevention of cancer in Barrett's esophagus.
  • This report describes the molecular mechanisms whereby acid exposure directly and indirectly, through inducing inflammation, may contribute to the neoplastic progression of Barrett's esophagus and the potential role for acid suppression as a chemopreventive strategy in patients with Barrett's esophagus.
  • [MeSH-major] Barrett Esophagus / complications. Esophageal Neoplasms / etiology. Gastroesophageal Reflux / complications

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19847948.001).
  • [ISSN] 0925-4692
  • [Journal-full-title] Inflammopharmacology
  • [ISO-abbreviation] Inflammopharmacology
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK63621
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Acids; 0 / Cytokines; 0 / NF-kappa B; 0 / Reactive Nitrogen Species; 0 / Reactive Oxygen Species
  • [Number-of-references] 53
  •  go-up   go-down


19. Piessen G, Wacrenier A, Briez N, Triboulet JP, Van Seuningen I, Mariette C: Clinical impact of MUC1 and MUC4 expression in Barrett-associated oesophageal adenocarcinoma. J Clin Pathol; 2009 Dec;62(12):1144-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical impact of MUC1 and MUC4 expression in Barrett-associated oesophageal adenocarcinoma.
  • AIMS: To study the expression of MUC1 and MUC4 mucins in Barrett-associated oesophageal adenocarcinoma and coexisting lesions of the carcinogenic sequence (normal mucosa, metaplasia, dysplasia) if present, and to investigate their prognostic significance.
  • METHODS: The expression profiles of MUC1 and MUC4 were investigated by immunohistochemistry in tissue samples obtained from consecutive patients with primary surgically resected lower third oesophageal adenocarcinoma (OA) between 1997 and 2002.
  • RESULTS: All 52 patients exhibited OA, with 25 patients (48.1%) having associated Barrett oesophagus lesions (metaplasia or/and dysplasia).
  • MUC1 and MUC4 were expressed in 52 and 41 of the 52 patients with adenocarcinoma (100% and 78%), respectively.
  • [MeSH-major] Adenocarcinoma / metabolism. Barrett Esophagus / metabolism. Biomarkers, Tumor / metabolism. Esophageal Neoplasms / metabolism. Mucin-1 / metabolism. Mucin-4 / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19946103.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / MUC4 protein, human; 0 / Mucin-1; 0 / Mucin-4; 0 / Neoplasm Proteins
  •  go-up   go-down


20. Cooper SC, Croft S, Day R, Thomson CS, Trudgill NJ: The risk of oesophageal cancer is not affected by a diagnosis of breast cancer. Eur J Cancer Prev; 2010 May;19(3):182-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The risk of oesophageal cancer is not affected by a diagnosis of breast cancer.
  • Oesophageal adenocarcinoma (OAC) is less common and develops at a later age in women compared with men.
  • A cohort of women with breast cancer, a tumour commonly treated with oestrogen antagonists, was examined to identify the subsequent risk of developing OAC.
  • Earlier studies have implicated radiotherapy in increasing oesophageal cancer (OC) risk among women with breast cancer.
  • West Midlands Cancer Intelligence Unit data recording cancer diagnosis and treatment information was examined to identify patients with a first malignant primary breast cancer during 1977-2004.
  • Patients were followed until diagnosis of a second primary cancer, death or end of the time period examined.
  • No difference was identified when examined by OC morphology.There was no association between breast cancer and a second primary OC.
  • Radiotherapy that avoids deep irradiation in the treatment of breast cancer, local nodes or recurrence was not associated with an increased risk of developing a second primary OC.
  • [MeSH-major] Breast Neoplasms / complications. Esophageal Neoplasms / etiology. Neoplasms, Second Primary / etiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20145541.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogens
  •  go-up   go-down


21. Bosetti C, Gallus S, Garavello W, La Vecchia C: Smoking cessation and the risk of oesophageal cancer: An overview of published studies. Oral Oncol; 2006 Nov;42(10):957-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smoking cessation and the risk of oesophageal cancer: An overview of published studies.
  • The epidemiologic studies on oesophageal cancer and smoking cessation published before December 2005 were reviewed here.
  • The results from at least 10 cohort and 10 case-control studies indicated that former smokers had a lower risk of squamous-cell or unspecified oesophageal cancer than current smokers.
  • Most investigations showed that the risk of oesophageal cancer remains elevated many years (at least 10) after cessation of smoking, to decline by about 40% only thereafter.
  • A few studies investigated the effect of smoking cessation on adenocarcinoma, and did not report a clear reduction of risk.
  • Data on oesophageal adenocarcinoma are however too limited to provide adequate inference on the relation with time since smoking cessation.
  • In conclusion, cessation of smoking could have an appreciable impact in reducing (squamous-cell) oesophageal cancer, and represents an obvious priority for prevention and public-health purposes.
  • [MeSH-major] Esophageal Neoplasms / epidemiology. Smoking / adverse effects. Smoking Cessation
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / etiology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / etiology. Case-Control Studies. Cohort Studies. Humans. Risk Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Quitting Smoking.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16919996.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U137686859
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 29
  •  go-up   go-down


22. Konda Vani JA, Chennat J, Waxman I: New directions in endoscopic therapy of Barrett' s esophagus. Minerva Gastroenterol Dietol; 2010 Dec;56(4):421-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New directions in endoscopic therapy of Barrett' s esophagus.
  • The key to prevention and early treatment of esophageal adenocarcinoma is the detection and eradication of neoplasia found in patients with Barrett's esophagus (BE).
  • The goals of endoscopic therapy of Barrett's neoplasia are to preserve the esophagus while ablating or removing the entire Barrett's segment.
  • Endoscopic resection is a tool to accurately provide a histological diagnosis of lesions in addition to treat neoplasia.
  • [MeSH-major] Adenocarcinoma / therapy. Barrett Esophagus / therapy. Esophageal Neoplasms / therapy. Esophagoscopy / trends. Precancerous Conditions / therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139541.001).
  • [ISSN] 1121-421X
  • [Journal-full-title] Minerva gastroenterologica e dietologica
  • [ISO-abbreviation] Minerva Gastroenterol Dietol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


23. Soma T, Kaganoi J, Kawabe A, Kondo K, Tsunoda S, Imamura M, Shimada Y: Chenodeoxycholic acid stimulates the progression of human esophageal cancer cells: A possible mechanism of angiogenesis in patients with esophageal cancer. Int J Cancer; 2006 Aug 15;119(4):771-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chenodeoxycholic acid stimulates the progression of human esophageal cancer cells: A possible mechanism of angiogenesis in patients with esophageal cancer.
  • Bile acids are known to promote the growth of gastrointestinal cancer.
  • In vitro, esophageal squamous cell carcinoma (ESCC) cells and esophageal adenocarcinoma cells were studied.
  • Our results suggest that bile acids, important constituents of duodenal fluid, stimulate the development of human esophageal cancer by promoting angiogenesis via the COX-2 pathway.
  • [MeSH-major] Chenodeoxycholic Acid / pharmacology. Esophageal Neoplasms / blood supply. Esophageal Neoplasms / pathology

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16557574.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / Vascular Endothelial Growth Factor A; 0GEI24LG0J / Chenodeoxycholic Acid; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


24. van Heijl M, Sprangers MA, de Boer AG, Lagarde SM, Reitsma HB, Busch OR, Tilanus HW, van Lanschot JJ, van Berge Henegouwen MI: Preoperative and early postoperative quality of life predict survival in potentially curable patients with esophageal cancer. Ann Surg Oncol; 2010 Jan;17(1):23-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative and early postoperative quality of life predict survival in potentially curable patients with esophageal cancer.
  • BACKGROUND: In patients with esophageal cancer, evidence for prognostic significance of preoperative quality of life (QoL) is limited, while the prognostic significance of postoperative QoL has not been investigated at all.
  • AIM: To determine whether preoperative and postoperative QoL measurements can predict survival independently from clinical and pathological factors, in patients with potentially curable esophageal adenocarcinoma.
  • CONCLUSION: In the present paper the first large consecutive series of potentially curable esophageal cancer patients is presented in whom prospectively collected QoL data before and after potentially curative surgical resection were used to predict survival.
  • Both preoperative (physical symptoms) and postoperative (social functioning, pain, and activity level) QoL subscales are independent predictors of survival in potentially curable patients with esophageal adenocarcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / mortality. Esophageal Neoplasms / mortality. Quality of Life

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2000 Dec;87(12):1716-21 [11122191.001]
  • [Cites] Biometrics. 2001 Mar;57(1):114-9 [11252585.001]
  • [Cites] Gut. 2001 Aug;49(2):227-30 [11454799.001]
  • [Cites] Ann Thorac Surg. 2001 Jul;72(1):306-13 [11465217.001]
  • [Cites] Eur J Cancer. 2002 Jul;38(10):1351-7 [12091066.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1662-9 [12444180.001]
  • [Cites] Br J Surg. 2003 Nov;90(11):1367-72 [14598416.001]
  • [Cites] Qual Life Res. 2004 Mar;13(2):311-20 [15085903.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2395-403 [15197201.001]
  • [Cites] Med Care. 1988 Jul;26(7):724-35 [3393032.001]
  • [Cites] Br J Cancer. 1990 Dec;62(6):1034-8 [2257209.001]
  • [Cites] J Clin Oncol. 1992 Dec;10(12):1833-8 [1453197.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):392-400; discussion 400-3 [10493486.001]
  • [Cites] Ann Oncol. 2005 Jul;16(7):1005-53 [15939716.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6865-72 [16192578.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4347-55 [16963732.001]
  • [Cites] Qual Life Res. 2006 Oct;15(8):1297-306 [16830258.001]
  • [Cites] Lancet Oncol. 2007 Mar;8(3):226-34 [17329193.001]
  • [Cites] Ann Thorac Surg. 2007 Apr;83(4):1257-64 [17383322.001]
  • [Cites] Br J Surg. 2007 Nov;94(11):1361-8 [17582230.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):992-1000; discussion 1000-1 [18043101.001]
  • [Cites] Br J Cancer. 2008 Mar 11;98(5):888-93 [18268490.001]
  • [Cites] J Clin Oncol. 2008 Mar 10;26(8):1355-63 [18227528.001]
  • [Cites] Endoscopy. 2008 Jun;40(6):464-71 [18543134.001]
  • [Cites] Ann Surg Oncol. 2008 Nov;15(11):3289-98 [18670823.001]
  • [CommentIn] Ann Surg Oncol. 2010 Jan;17(1):12-3 [19851809.001]
  • (PMID = 19830496.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2805800
  •  go-up   go-down


25. Chung SM, Kao J, Hyjek E, Chen YT: p53 in esophageal adenocarcinoma: a critical reassessment of mutation frequency and identification of 72Arg as the dominant allele. Int J Oncol; 2007 Dec;31(6):1351-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 in esophageal adenocarcinoma: a critical reassessment of mutation frequency and identification of 72Arg as the dominant allele.
  • p53 alterations have been implicated in the progression of Barrett's esophagus to esophageal adenocarcinoma.
  • However, the wide range of reported p53 alteration frequencies in esophageal adenocarcinoma makes using p53 as a marker of malignant transformation of Barrett's esophagus problematic.
  • To determine the utility of p53 in Barrett's esophagus monitoring, the frequency of p53 alteration was critically reassessed using esophagectomy specimens of 40 cases of esophageal adenocarcinoma, including 10 with Barrett's esophagus and high-grade dysplasia, 8 with low-grade dysplasia and 7 with no dysplasia.
  • Mutations in p53 were identified in 75% (30/40) of the esophageal adenocarcinoma. p53 protein overexpression, detected by immunohistochemistry, was found in 58% (23/40) of the esophageal adenocarcinoma, 60% (6/10) of Barrett's esophagus with high-grade dysplasia, 12% (1/8) of Barrett's esophagus with low-grade dysplasia, and 0% of Barrett's esophagus without dysplasia.
  • However, p53 appeared to be a late marker in the neoplastic transformation, and no p53 change was found in approximately 25% of the adenocarcinoma.
  • We concluded that p53 is insufficient as a single marker for Barrett's esophagus monitoring but may be useful as part of a panel due to its high specificity.
  • [MeSH-major] Adenocarcinoma / genetics. Alleles. Esophageal Neoplasms / genetics. Genes, p53. Mutation

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17982662.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


26. Sharma P, Wani S, Bansal A: The quest for intestinal metaplasia--is it worth the effort? Am J Gastroenterol; 2007 Jun;102(6):1162-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The columnar-lined esophagus (CLE) has remained an enigma for several decades.
  • Starting with the basics, the definition and diagnosis of Barrett's esophagus (BE) continues to be a point of major debate globally leading to definitions that have been restrictive (requiring histologically confirmed intestinal metaplasia) or all-encompassing (simply the presence of CLE at endoscopy).
  • The interest in intestinal metaplasia stems from studies that have consistently demonstrated intestinal metaplasia and dysplasia both adjacent to and remote from esophageal adenocarcinoma.
  • There is ample evidence that once a diagnosis of BE is made, it has significant implications on the financial, psychosocial, and insurance status of the patients.
  • We feel that an optimal, practical definition of BE requires clear, accepted, reproducible, and clinically relevant criteria with evidence of an increased risk of cancer--the most crucial consequence of the lesion--and discuss the pros and cons of the need for documenting intestinal metaplasia in the CLE.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Biopsy. Diagnostic Imaging. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / pathology. Gastric Mucosa / pathology. Humans. Metaplasia. Precancerous Conditions / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Gastroenterol. 2007 Jun;102(6):1154-61 [17433019.001]
  • (PMID = 17531009.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down


27. Lisovsky M, Falkowski O, Bhuiya T: Expression of alpha-methylacyl-coenzyme A racemase in dysplastic Barrett's epithelium. Hum Pathol; 2006 Dec;37(12):1601-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although identification of epithelial dysplasia in Barrett's esophagus (BE) is critically important because of a significant risk of progression to invasive adenocarcinoma, the diagnosis of dysplasia may be challenging.
  • Among confounding factors are interobserver variability, tangential sectioning, and severe mucosal inflammation leading to architectural and cytologic atypia similar to that of dysplasia. alpha-methylacyl-coenzyme A racemase (AMACR) is an enzyme involved in beta-oxidation of branched fatty acids and an established marker of prostate cancer.
  • Ninety-six routinely processed biopsy and/or resection specimens (23 negative for dysplasia; 19, low-grade dysplasia; 22, high-grade dysplasia; 16, reactive atypia; and 16, esophageal adenocarcinoma) were immunostained using a monoclonal anti-AMACR antibody p504S.
  • Of 16 specimens, 12 (75%) showed positive staining for AMACR in the adenocarcinoma group.
  • [MeSH-major] Barrett Esophagus / enzymology. Racemases and Epimerases / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16996568.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


28. Michor F, Polyak K: The origins and implications of intratumor heterogeneity. Cancer Prev Res (Phila); 2010 Nov;3(11):1361-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This phenotypic and genetic heterogeneity plays an important role in neoplasia, cancer progression, and therapeutic resistance.
  • In this issue of the journal (beginning on page 1388), Merlo et al. report their use of molecular data from 239 patients with Barrett's esophagus to evaluate the propensity of major diversity indices for predicting progression to esophageal adenocarcinoma.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Cell Stem Cell. 2010 Feb 5;6(2):141-52 [20144787.001]
  • [Cites] J Clin Invest. 2010 Feb;120(2):636-44 [20101094.001]
  • [Cites] Cancer Prev Res (Phila). 2010 May;3(5):579-87 [20424132.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Nov;3(11):1388-97 [20947487.001]
  • [Cites] Science. 2000 Sep 8;289(5485):1754-7 [10976069.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Genetics. 2003 Apr;163(4):1527-32 [12702695.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6212-20 [14559806.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6635-42 [14583456.001]
  • [Cites] J Theor Biol. 2003 Dec 7;225(3):377-82 [14604590.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14966-9 [14657359.001]
  • [Cites] Bull Math Biol. 2004 Jul;66(4):663-87 [15210312.001]
  • [Cites] Oncogene. 2004 Sep 20;23(43):7274-82 [15378087.001]
  • [Cites] Cancer Res. 1978 Sep;38(9):2651-60 [354778.001]
  • [Cites] Cancer Treat Rep. 1983 Oct;67(10):923-31 [6627236.001]
  • [Cites] Cancer Res. 1984 Jun;44(6):2259-65 [6372991.001]
  • [Cites] Nature. 2005 Jun 30;435(7046):1267-70 [15988530.001]
  • [Cites] Semin Cell Dev Biol. 2005 Aug-Oct;16(4-5):554-63 [16144692.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):899-904 [16327766.001]
  • [Cites] Blood. 2010 Mar 11;115(10):1976-84 [20053758.001]
  • [Cites] Curr Pharm Des. 2006;12(3):261-71 [16454743.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):1891-5; discussion 1890 [16488984.001]
  • [Cites] Nat Genet. 2006 Apr;38(4):468-73 [16565718.001]
  • [Cites] J Theor Biol. 2006 Jun 21;240(4):521-30 [16343545.001]
  • [Cites] Leuk Lymphoma. 2006 Oct;47(10):2017-27 [17071472.001]
  • [Cites] Nat Rev Cancer. 2006 Dec;6(12):924-35 [17109012.001]
  • [Cites] Cell Cycle. 2007 Feb 15;6(4):461-6 [17329969.001]
  • [Cites] Semin Cancer Biol. 2007 Jun;17(3):204-13 [16787749.001]
  • [Cites] Oncogene. 2007 Apr 26;26(19):2695-706 [17057735.001]
  • [Cites] Cell Cycle. 2007 Oct 1;6(19):2332-8 [17786053.001]
  • [Cites] PLoS Comput Biol. 2007 Dec;3(12):e250 [18085819.001]
  • [CommentOn] Cancer Prev Res (Phila). 2010 Nov;3(11):1388-97 [20947487.001]
  • (PMID = 20959519.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U54 CA143798; United States / NCI NIH HHS / CA / U54CA143798
  • [Publication-type] Comment; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS240068; NLM/ PMC3633425
  •  go-up   go-down


29. Jenkins GJ, D'Souza FR, Suzen SH, Eltahir ZS, James SA, Parry JM, Griffiths PA, Baxter JN: Deoxycholic acid at neutral and acid pH, is genotoxic to oesophageal cells through the induction of ROS: The potential role of anti-oxidants in Barrett's oesophagus. Carcinogenesis; 2007 Jan;28(1):136-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deoxycholic acid at neutral and acid pH, is genotoxic to oesophageal cells through the induction of ROS: The potential role of anti-oxidants in Barrett's oesophagus.
  • Bile acids are often refluxed into the lower oesophagus and are candidate carcinogens in the development of oesophageal adenocarcinoma.
  • The higher levels of cell death and low cell survival rates at acidic pH may imply that acid bile exposure is toxic rather than carcinogenic, as dead cells do not seed cancer development.
  • [MeSH-major] Antioxidants / therapeutic use. Barrett Esophagus / metabolism. DNA Damage / drug effects. Deoxycholic Acid / toxicity. Detergents / toxicity. Reactive Oxygen Species / metabolism
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Ascorbic Acid / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / metabolism. Cell Survival / drug effects. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / metabolism. Humans. Hydrogen-Ion Concentration. Micronucleus Tests. Tumor Cells, Cultured. Tumor Suppressor Protein p53

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • Hazardous Substances Data Bank. DEOXYCHOLIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16905748.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Detergents; 0 / Reactive Oxygen Species; 0 / Tumor Suppressor Protein p53; 005990WHZZ / Deoxycholic Acid; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


30. Lugli A, Spichtin H, Maurer R, Mirlacher M, Kiefer J, Huusko P, Azorsa D, Terracciano L, Sauter G, Kallioniemi OP, Mousses S, Tornillo L: EphB2 expression across 138 human tumor types in a tissue microarray: high levels of expression in gastrointestinal cancers. Clin Cancer Res; 2005 Sep 15;11(18):6450-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: EphB2 protein expression was analyzed by immunohistochemistry on tissue microarrays that included 76 different normal tissues, >4,000 samples from 138 different cancer types, and 1,476 samples of colon cancer with clinical follow-up data.
  • RESULTS: We found most prominent EphB2 expression in the intestinal epithelium (colonic crypts) with cancer of the colorectum displaying the highest EphB2 positivity of all tumors.
  • EphB2 expression was also observed in 75 tumor categories, including serous carcinoma of the endometrium (34.8%), adenocarcinoma of the esophagus (33.3%), intestinal adenocarcinoma of the stomach (30.2%), and adenocarcinoma of the small intestine (70%).
  • The occasional finding of strong EphB2 positivity in tumors without EphB2 positivity in the corresponding normal cells [adenocarcinoma of the lung (4%) and pancreas (2.2%)] suggests that deregulation of EphB2 signaling may involve up-regulation of the protein expression.
  • Deregulated EphB2 expression may play a role in several cancer types with loss of EphB2 expression serving as an indicator of the possible pathogenetic role of EphB2 signaling in the maintenance of tissue architecture of colon epithelium.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166419.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, EphB2
  •  go-up   go-down


31. Quaroni L, Casson AG: Characterization of Barrett esophagus and esophageal adenocarcinoma by Fourier-transform infrared microscopy. Analyst; 2009 Jun;134(6):1240-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of Barrett esophagus and esophageal adenocarcinoma by Fourier-transform infrared microscopy.
  • The objective of this exploratory study was to evaluate the feasibility of using Fourier-Transform Infrared (FTIR) spectromicroscopy to characterize formalin-fixed, paraffin-embedded human esophageal tissues.
  • Matched histologically normal esophageal squamous epithelium (NS), premalignant Barrett esophagus (BE), and primary esophageal adenocarcinoma (EADC) tissues, each defined according to strict clinicopathologic criteria, were obtained from patients who underwent esophageal resection.
  • Normal esophageal epithelia were characterized by a few well defined regions, mostly of large size (tens of contiguous pixels), which correlated with tissue histology, specifically the basal cell layer.
  • The technical feasibility of using FTIR to characterize formalin-fixed, paraffin-embedded human esophageal tissues demonstrates the potential of this technique to study archival human BE tissue specimens via automated screening techniques.
  • [MeSH-major] Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Spectroscopy, Fourier Transform Infrared / methods
  • [MeSH-minor] Adenocarcinoma / pathology. Cluster Analysis. Goblet Cells / cytology. Goblet Cells / pathology. Humans. Intestines / pathology. Light. Metaplasia / pathology. Microscopy. Synchrotrons

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19475154.001).
  • [ISSN] 1364-5528
  • [Journal-full-title] The Analyst
  • [ISO-abbreviation] Analyst
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


32. Javle M, Ailawadhi S, Yang GY, Nwogu CE, Schiff MD, Nava HR: Palliation of malignant dysphagia in esophageal cancer: a literature-based review. J Support Oncol; 2006 Sep;4(8):365-73, 379
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliation of malignant dysphagia in esophageal cancer: a literature-based review.
  • Esophageal cancer is a lethal malignancy and adenocarcinoma of the esophagus is increasing in incidence.
  • The 5-year survival rate of patients with esophageal cancer is < 20%.
  • Palliation is an important goal of esophageal cancer therapy.
  • Investigation of dysphagia includes radiographic studies such as barium or Gastrografin swallow, esophagogastroduodenoscopy, endoscopic ultrasonography, and other staging studies for esophageal cancer.
  • Current management options for the palliation of dysphagia include esophageal dilatation, intraluminal stents, Nd:YAG laser therapy, photodynamic therapy, argon laser, systemic chemotherapy, external beam radiation therapy, brachytherapy, and combined chemoradiation therapy.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / therapy. Deglutition Disorders / etiology. Deglutition Disorders / therapy. Esophageal Neoplasms / complications. Esophageal Neoplasms / therapy. Palliative Care / methods


33. Mukherjee K, Chakravarthy AB, Goff LW, El-Rifai W: Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy. Dig Dis Sci; 2010 Dec;55(12):3304-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy.
  • Esophageal adenocarcinoma is an aggressive malignancy with a poor outcome, and its incidence continues to rise at an alarming rate.
  • Multiple molecular pathways including the epidermal growth factor receptor, vascular endothelial growth factor, v-erb-b2 erythroblastic leukemia viral oncogene homolog (ERBB2), and Aurora kinase pathways are activated in many esophageal adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / drug therapy. Esophageal Neoplasms / drug therapy. Molecular Targeted Therapy
  • [MeSH-minor] Angiogenesis Inhibitors / pharmacology. Antineoplastic Agents / pharmacology. Aurora Kinases. Barrett Esophagus / pathology. Clinical Trials as Topic. Combined Modality Therapy. Disease Progression. Esophagectomy. Humans. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Protein-Serine-Threonine Kinases / pharmacology. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / drug effects. Receptor, Epidermal Growth Factor / physiology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 2004 Aug 1;87(2):95-104 [15282704.001]
  • [Cites] Mod Pathol. 2004 Oct;17(10):1282-8 [15167938.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):747-53 [15386389.001]
  • [Cites] Ann Thorac Surg. 2004 Nov;78(5):1790-800 [15511476.001]
  • [Cites] Surg Gynecol Obstet. 1981 Nov;153(5):690-2 [6794167.001]
  • [Cites] World J Surg. 1987 Aug;11(4):426-32 [3630187.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Feb;16(2):325-7 [2646253.001]
  • [Cites] Br J Surg. 1990 Aug;77(8):845-57 [2203505.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] World J Surg. 1992 Nov-Dec;16(6):1104-9; discussion 1110 [1455880.001]
  • [Cites] Int J Cancer. 1993 May 8;54(2):213-9 [8098013.001]
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):462-7 [8672151.001]
  • [Cites] Am J Surg. 1997 Sep;174(3):320-4 [9324146.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Sep;12(3):361-4; discussion 364-5 [9332912.001]
  • [Cites] Ann Thorac Surg. 1998 Mar;65(3):787-92 [9527214.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):579-83 [9635705.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):189-93 [9771714.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2008 Aug;295(2):G211-8 [18556417.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1184-7 [18695138.001]
  • [Cites] Cancer Lett. 2009 Mar 18;275(2):170-7 [18703277.001]
  • [Cites] J Hepatol. 2009 Mar;50(3):518-27 [19155085.001]
  • [Cites] Oncogene. 2009 Feb 12;28(6):866-75 [19060929.001]
  • [Cites] J Thorac Cardiovasc Surg. 2009 Mar;137(3):587-95; discussion 596 [19258071.001]
  • [Cites] Gastroenterol Clin North Am. 2009 Mar;38(1):135-52, ix [19327572.001]
  • [Cites] Expert Opin Investig Drugs. 2009 Apr;18(4):379-98 [19335272.001]
  • [Cites] J Am Coll Surg. 2009 Apr;208(4):553-6 [19476789.001]
  • [Cites] Mol Cancer Ther. 2009 Jun;8(6):1547-56 [19509244.001]
  • [Cites] Ann Oncol. 2009 Sep;20(9):1522-8 [19465425.001]
  • [Cites] World J Gastroenterol. 2009 Dec 21;15(47):5983-91 [20014464.001]
  • [Cites] Breast Cancer Res Treat. 2010 Feb;120(1):47-57 [19301121.001]
  • [Cites] Clin Colorectal Cancer. 2010 Jan;9(1):8-14 [20100683.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4922-7 [17050876.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5201-6 [17114652.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):6869-75 [17145803.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):120-9 [17143264.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):405-9 [17097832.001]
  • [Cites] Cancer Sci. 2007 Mar;98(3):357-63 [17270025.001]
  • [Cites] Cancer. 2007 Feb 15;109(4):658-67 [17211865.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):510-7 [17164226.001]
  • [Cites] Lancet Oncol. 2007 Mar;8(3):226-34 [17329193.001]
  • [Cites] Oncogene. 2007 Mar 29;26(14):2006-16 [17001310.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12480-4 [18711136.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5437-46 [18765535.001]
  • [Cites] Biochim Biophys Acta. 2008 Sep;1786(1):60-72 [18662747.001]
  • [Cites] APMIS. 2008 Jul-Aug;116(7-8):629-37 [18834407.001]
  • [Cites] Am J Clin Oncol. 2008 Aug;31(4):329-34 [18845990.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8998-9004 [18974145.001]
  • [Cites] Carcinogenesis. 2008 Dec;29(12):2330-4 [18780893.001]
  • [Cites] Gut. 2009 Jan;58(1):5-15 [18664505.001]
  • [Cites] Cancer Lett. 2009 Mar 8;275(1):117-26 [19027227.001]
  • [Cites] J Gastrointest Surg. 2009 Feb;13(2):212-22 [18854960.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):16-23; discussion 23-5 [9869753.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] JAMA. 1999 May 5;281(17):1623-7 [10235156.001]
  • [Cites] World J Surg. 1999 Oct;23(10):1010-8 [10512940.001]
  • [Cites] Cancer Invest. 2004;22(5):670-7 [15581047.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):203-11 [15629613.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] J Am Coll Surg. 2005 Mar;200(3):336-44 [15737843.001]
  • [Cites] Oncogene. 2005 Jul 28;24(32):5005-15 [16049526.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6583-92 [16061638.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):659-68 [16129366.001]
  • [Cites] Ann Surg. 2005 Oct;242(4):566-73; discussion 573-5 [16192817.001]
  • [Cites] Neoplasia. 2005 Sep;7(9):854-61 [16229808.001]
  • [Cites] Surgery. 2005 Nov;138(5):924-31 [16291394.001]
  • [Cites] Anticancer Drugs. 2006 Jan;17(1):95-102 [16317296.001]
  • [Cites] Cancer Causes Control. 2006 Feb;17(1):81-3 [16411056.001]
  • [Cites] Ann Surg Oncol. 2006 Feb;13(2):214-20 [16418887.001]
  • [Cites] Int J Cancer. 2006 Apr 1;118(7):1814-22 [16217753.001]
  • [Cites] Ann Surg. 2006 Mar;243(3):334-40 [16495697.001]
  • [Cites] Radiother Oncol. 2006 Mar;78(3):236-44 [16545878.001]
  • [Cites] Arch Surg. 2006 May;141(5):476-81; discussion 481-2 [16702519.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Mol Cancer Res. 2006 Jul;4(7):449-55 [16849520.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(3):CD001556 [16855972.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4283-7 [16857803.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Aug;3(8):448-57 [16894390.001]
  • [Cites] Diagn Mol Pathol. 2006 Sep;15(3):125-30 [16932066.001]
  • [Cites] Neoplasia. 2007 Apr;9(4):341-8 [17460778.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):3100-4 [17505013.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):1-8 [17592282.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5869-75 [17908981.001]
  • [Cites] J Am Coll Surg. 2007 Dec;205(6):735-40 [18035255.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):391-5 [17980508.001]
  • [Cites] Ann Thorac Surg. 2008 Feb;85(2):424-9 [18222237.001]
  • [Cites] Arthritis Rheum. 2008 Feb;58(2):571-6 [18240225.001]
  • [Cites] PLoS One. 2008;3(4):e1890 [18382671.001]
  • [Cites] Cancer. 2008 Apr 15;112(8):1688-98 [18311783.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3077-80; discussion 3080 [18451130.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3081-6; discussion 3086 [18451131.001]
  • [Cites] Anesthesiol Clin. 2008 Jun;26(2):293-304, vi [18456214.001]
  • [Cites] Scand J Gastroenterol. 2007 Dec;42(12):1460-5 [17852856.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Jun;135(6):1228-36 [18544359.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1380-5 [18559552.001]
  • [Cites] Oncology. 2007;73(5-6):281-9 [18477853.001]
  • [Cites] Hepatogastroenterology. 2008 Mar-Apr;55(82-83):475-81 [18613391.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4564-71 [18579663.001]
  • [Cites] J Thorac Cardiovasc Surg. 2000 Feb;119(2):277-88 [10649203.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):35-9 [10665910.001]
  • [Cites] Recent Results Cancer Res. 2000;155:29-41 [10693236.001]
  • [Cites] J Gastroenterol Hepatol. 2000 Jul;15(7):730-6 [10937677.001]
  • [Cites] Chest Surg Clin N Am. 2000 Aug;10(3):451-69 [10967750.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):592-8 [11522743.001]
  • [Cites] J Cell Biol. 2002 Feb 4;156(3):437-51 [11827981.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1727-33 [12049861.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4061-4 [12124342.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1662-9 [12444180.001]
  • [Cites] Arch Surg. 2003 Mar;138(3):303-8 [12611579.001]
  • [Cites] Am J Surg. 2003 Jun;185(6):538-43 [12781882.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6461-8 [14695149.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1561-9 [14996709.001]
  • [Cites] J Gastrointest Surg. 2004 May-Jun;8(4):448-53 [15120370.001]
  • [Cites] Gut. 2004 Jul;53(7):925-30 [15194636.001]
  • (PMID = 20300841.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1 UL1 RR024975; United States / NCI NIH HHS / CA / T32 CA106183-04; United States / NCI NIH HHS / CA / T32 CA106183; United States / NCRR NIH HHS / RR / TL1 RR024978; United States / NCRR NIH HHS / RR / KL2 RR024977; United States / NCI NIH HHS / CA / R01 CA133738-01A2; United States / NCI NIH HHS / CA / R01 CA106176-07A1; United States / NCI NIH HHS / CA / CA133738; United States / NCI NIH HHS / CA / CA131225; United States / NCI NIH HHS / CA / R01 CA131225-01A2; United States / NCI NIH HHS / CA / R01 CA133738; United States / NCI NIH HHS / CA / R01 CA106176; United States / NCI NIH HHS / CA / R01 CA131225; United States / NCI NIH HHS / CA / T32 CA106183-05; United States / NCRR NIH HHS / RR / UL1 RR024975; United States / NCRR NIH HHS / RR / UL1 RR024975-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ NIHMS183809; NLM/ PMC2890301
  •  go-up   go-down


34. Raggi M, Langer R, Feith M, Friess H, Schauer M, Theisen J: Successful evaluation of a new animal model using mice for esophageal adenocarcinoma. Langenbecks Arch Surg; 2010 Apr;395(4):347-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful evaluation of a new animal model using mice for esophageal adenocarcinoma.
  • INTRODUCTION: For the better understanding of the pathophysiological events occurring in the sequence inflammation-metaplasia-carcinoma in esophageal adenocarcinoma, an animal model would be desirable.
  • Some demonstrated a sequence similar to the human situation whereas others failed to initiate true esophageal adenocarcinoma or even Barrett's metaplasia.
  • Intestinal metaplasia could be found in 60% of the animals after 4 months and esophageal adenocarcinoma in 55% after 5 months.
  • CONCLUSION: After a certain learning curve esophagojejunostomy is feasible in mice with an acceptable mortality rate and leads to esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagus / surgery. Jejunum / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Res. 2000 Jun 15;91(2):111-7 [10839958.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):57-67 [15213619.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Oct;122(4):809-14 [11581618.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):185-9 [8054264.001]
  • [Cites] Scand J Gastroenterol. 2003 Jul;38(7):687-92 [12889552.001]
  • [Cites] Int J Cancer. 1996 Jul 17;67(2):269-74 [8760598.001]
  • [Cites] Carcinogenesis. 2000 Aug;21(8):1587-91 [10910963.001]
  • [Cites] Carcinogenesis. 2000 Feb;21(2):257-63 [10657966.001]
  • [Cites] J Gastrointest Surg. 1998 May-Jun;2(3):260-8 [9841983.001]
  • [Cites] Carcinogenesis. 1997 Nov;18(11):2265-70 [9395230.001]
  • [Cites] J Surg Res. 2006 Oct;135(2):337-44 [16926029.001]
  • [Cites] J Surg Res. 1999 May 1;83(1):48-55 [10210642.001]
  • [Cites] Anticancer Res. 2002 Jan-Feb;22(1A):39-44 [12017320.001]
  • (PMID = 20300770.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


35. Aklilu M, Ilson DH: Targeted agents and esophageal cancer--the next step? Semin Radiat Oncol; 2007 Jan;17(1):62-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted agents and esophageal cancer--the next step?
  • Esophageal cancer (EC) is an aggressive cancer and is a leading cause of cancer-related death worldwide.
  • In the United States and Western Europe, there has been a decline in the incidence of squamous cell carcinomas coupled with a rapid rise in incidence of adenocarcinoma of the esophagus and gastroesophageal junction.
  • [MeSH-major] Esophageal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17185199.001).
  • [ISSN] 1053-4296
  • [Journal-full-title] Seminars in radiation oncology
  • [ISO-abbreviation] Semin Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Cyclooxygenase 2 Inhibitors; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 85
  •  go-up   go-down


36. Wen D, Zhang N, Shan B, Wang S: Helicobacter pylori infection may be implicated in the topography and geographic variation of upper gastrointestinal cancers in the Taihang Mountain high-risk region in northern China. Helicobacter; 2010 Oct;15(5):416-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic infection of the bacterial not only causes distal stomach cancer, but also confers risk to gastric cardia adenocarcinoma.
  • Because H. pylori infection is inversely associated with esophageal adenocarcinoma, globally the infection rate is significantly correlated with the ratio of squamous carcinoma to adenocarcinoma of the esophagus.
  • These agree with the topography of upper gastrointestinal cancer observed in the Taihang Mountain high-risk region where both gastric cardia and non-cardia adenocarcinoma coincide with esophageal squamous cancer, but with almost no distal esophageal adenocarcinoma.
  • Because H. pylori infection is a definite carcinogen to gastric adenocarcinoma and is more prevalent in the mountain than in plain areas due to undeveloped living conditions, the observation gives the impression as though H. pylori infection is implicated.
  • AIMS: This article aims to note the role of H. pylori infection in upper gastrointestinal cancer in the Taihang Mountain high-risk region in northern China.
  • MATERIALS AND METHODS: First the unique topography and geographic variation of upper gastrointestinal cancer in the region is described to indicate a possible role of H. pylori infection, then we review studies on prevalence of H. pylori infection in the high-risk region and describe difference in socioeconomic development and water hygiene between the plains and the mountains as related to the prevalence of H. pylori infection.
  • RESULTS:   Coincidence of gastric cancer in the region and a progressively increasing rate of the cancer from the plain towards the mountains indicate H. pylori infection may be implicated in upper gastrointestinal cancer.
  • CONCLUSION: International collaboration is needed to study H. pylori and upper gastrointestinal cancer in the region when rapid industrialization is just beginning.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / microbiology. Gastrointestinal Neoplasms / epidemiology. Gastrointestinal Neoplasms / microbiology. Helicobacter Infections / complications. Helicobacter Infections / epidemiology. Helicobacter pylori / isolation & purification

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 21083747.001).
  • [ISSN] 1523-5378
  • [Journal-full-title] Helicobacter
  • [ISO-abbreviation] Helicobacter
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Labutina IuO: [Barrett's esophagus: contemporary diagnostic and therapeutic approaches]. Klin Med (Mosk); 2006;84(11):25-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Barrett's esophagus: contemporary diagnostic and therapeutic approaches].
  • The author considers the modern concepts of the epidemiology, pathophysiology, clinical manifestations, and diagnostics of Barrett's esophagus (BE).
  • Special attention is paid to the evaluation of BE as precancer elevating the risk of esophageal adenocarcinoma, as well as the issues of the treatment and regular medical check-up of such patients.
  • [MeSH-major] Barrett Esophagus. Endoscopy, Gastrointestinal / methods. Enzyme Inhibitors / therapeutic use. Esophagectomy / methods. Histamine H2 Antagonists / therapeutic use. Proton Pump Inhibitors

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17243606.001).
  • [ISSN] 0023-2149
  • [Journal-full-title] Klinicheskaia meditsina
  • [ISO-abbreviation] Klin Med (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Histamine H2 Antagonists; 0 / Proton Pump Inhibitors
  • [Number-of-references] 39
  •  go-up   go-down


38. Wu G, Bybel B, Brunken R, Lin H, Neumann D: PET detection of solitary distant skeletal muscle metastasis of esophageal adenocarcinoma. Clin Nucl Med; 2005 May;30(5):335-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET detection of solitary distant skeletal muscle metastasis of esophageal adenocarcinoma.
  • A 67-year-old man with progressive dysphagia was recently diagnosed with a gastroesophageal junction adenocarcinoma.
  • Needle biopsy was performed and confirmed metastatic esophageal adenocarcinoma.
  • A case of skeletal muscle metastases from late-stage (IV) gastroesophageal adenocarcinoma was previously reported.
  • The case supports the previous report that PET is superior in detecting distant metastases for initial staging of esophageal carcinoma over CT.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Adenocarcinoma / secondary. Esophageal Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Muscle Neoplasms / radionuclide imaging. Muscle Neoplasms / secondary. Positron-Emission Tomography / methods

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15827406.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


39. Lin L, Wang Z, Prescott MS, van Dekken H, Thomas DG, Giordano TJ, Chang AC, Orringer MB, Gruber SB, Moran JV, Glover TW, Beer DG: Multiple forms of genetic instability within a 2-Mb chromosomal segment of 3q26.3-q27 are associated with development of esophageal adenocarcinoma. Genes Chromosomes Cancer; 2006 Apr;45(4):319-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple forms of genetic instability within a 2-Mb chromosomal segment of 3q26.3-q27 are associated with development of esophageal adenocarcinoma.
  • Gene amplification is one of the mechanisms to activate oncogenes in many cancers, including esophageal adenocarcinoma (EA).
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 3. Esophageal Neoplasms / genetics


40. Takubo K, Aida J, Sawabe M, Arai T, Kato H, Pech O, Arima M: The normal anatomy around the oesophagogastric junction: a histopathologic view and its correlation with endoscopy. Best Pract Res Clin Gastroenterol; 2008;22(4):569-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of primary oesophageal adenocarcinoma in Caucasian men has recently been increasing rapidly.
  • Therefore, primary oesophageal adenocarcinoma, columnar-lined oesophagus (CLO) or Barrett's oesophagus and the normal condition of the lower segment of the oesophagus are currently receiving worldwide attention in the medical field.
  • We review definitions of the OGJ, the pattern of the squamocolumnar junction (SCJ), oesophageal cardiac-type glands beneath the squamous epithelium, the normal squamous epithelium, columnar islands in squamous-lined mucosa, squamous islands in CLO and newly reported metaplastic changes in the OGJ zone.
  • [MeSH-minor] Biopsy. Esophageal Sphincter, Upper / cytology. Humans. Stomach / cytology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656817.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 33
  •  go-up   go-down


41. Szachnowicz S, Cecconello I, Ribeiro U, Iriya K, El Ibrahim R, Takeda FR, Corbett CE, Vaz Safatle-Ribeiro A: Mucin pattern reflects the origin of the adenocarcinoma in Barrett's esophagus: a retrospective clinical and laboratorial study. World J Surg Oncol; 2009;7:27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucin pattern reflects the origin of the adenocarcinoma in Barrett's esophagus: a retrospective clinical and laboratorial study.
  • BACKGROUND: Mucin immunoexpression in adenocarcinoma arising in Barrett's esophagus (BE) may indicate the carcinogenesis pathway.
  • The aim of this study was to evaluate resected specimens of adenocarcinoma in BE for the pattern of mucins and to correlate to the histologic classification.
  • METHODS: Specimens were retrospectively collected from thirteen patients who underwent esophageal resection due to adenocarcinoma in BE.
  • CONCLUSION: Barrett's esophagus adenocarcinoma shows either gastric or intestinal type pattern of mucin expression.
  • The two types of tumors developed in Barrett's esophagus may reflect the original cell type involved in the malignant transformation.
  • [MeSH-major] Adenocarcinoma / etiology. Barrett Esophagus / complications. Esophageal Neoplasms / etiology. Mucin 5AC / analysis. Mucin-2 / analysis

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1999 Dec;35(6):517-24 [10583575.001]
  • [Cites] Clinics (Sao Paulo). 2005 Apr;60(2):103-12 [15880245.001]
  • [Cites] Gut. 2000 Dec;47(6):753-61 [11076872.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):660-8 [12152167.001]
  • [Cites] Gan. 1968 Jun;59(3):251-8 [5726267.001]
  • [Cites] Histochem J. 1981 Nov;13(6):931-9 [7338482.001]
  • [Cites] Hum Pathol. 1983 Jan;14(1):42-61 [6832749.001]
  • [Cites] Am J Clin Pathol. 1984 Apr;81(4):500-3 [6702752.001]
  • [Cites] Am J Surg. 1985 Sep;150(3):365-9 [4037198.001]
  • [Cites] Gut. 1986 Sep;27(9):1062-8 [3758820.001]
  • [Cites] J Biol Chem. 1989 Apr 15;264(11):6480-7 [2703501.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1989;414(4):359-63 [2496524.001]
  • [Cites] Cancer. 1991 Oct 15;68(8):1731-6 [1913516.001]
  • [Cites] Crit Rev Biochem Mol Biol. 1992;27(1-2):57-92 [1727693.001]
  • [Cites] Dig Dis Sci. 1992 Jan;37(1):137-43 [1728519.001]
  • [Cites] Gastroenterol Clin North Am. 1991 Dec;20(4):817-34 [1787015.001]
  • [Cites] Am J Gastroenterol. 1992 Jun;87(6):746-50 [1590313.001]
  • [Cites] Am J Respir Cell Mol Biol. 1992 Dec;7(6):557-64 [1449803.001]
  • [Cites] Cancer Res. 1993 Feb 1;53(3):641-51 [7678777.001]
  • [Cites] J Histochem Cytochem. 1993 Oct;41(10):1479-85 [8245407.001]
  • [Cites] J Biol Chem. 1994 Jan 28;269(4):2440-6 [8300571.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):973-81 [8144002.001]
  • [Cites] Gastroenterology. 1994 Jul;107(1):28-36 [8020672.001]
  • [Cites] Lancet. 1994 Dec 3;344(8936):1533-6 [7983953.001]
  • [Cites] Am J Surg Pathol. 1995 Feb;19(2):183-91 [7832278.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2681-90 [7780985.001]
  • [Cites] Biochem J. 1995 Jul 1;309 ( Pt 1):221-9 [7619060.001]
  • [Cites] Gastroenterology. 1995 Nov;109(5):1541-6 [7557137.001]
  • [Cites] Biochem Soc Trans. 1995 Nov;23(4):795-9 [8654840.001]
  • [Cites] Biochem Soc Trans. 1995 Nov;23(4):840-5 [8654850.001]
  • [Cites] Am J Gastroenterol. 1997 Mar;92(3):414-8 [9068460.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1028-32 [9672324.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1003-7 [10070955.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):965-73 [10233832.001]
  • [Cites] Ann Surg. 2000 Mar;231(3):303-21 [10714623.001]
  • (PMID = 19272137.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-2
  • [Other-IDs] NLM/ PMC2662840
  •  go-up   go-down


42. Siewert JR, Lordick F, Ott K, Stein HJ, Weber WA, Becker K, Peschel C, Fink U, Schwaiger M: Induction chemotherapy in Barrett cancer: influence on surgical risk and outcome. Ann Surg; 2007 Oct;246(4):624-8; discussion 628-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemotherapy in Barrett cancer: influence on surgical risk and outcome.
  • OBJECTIVE: To study the impact of induction chemotherapy on surgical risk and outcome in locally advanced Barrett cancer.
  • BACKGROUND: Induction chemotherapy has become an accepted choice for the treatment of locally advanced adenocarcinoma of the esophagus and the esophagogastric junction.
  • CONCLUSIONS: Induction chemotherapy and early metabolic response assessment is a new concept in the treatment of locally advanced Barrett cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Barrett Esophagus / surgery. Esophageal Neoplasms / surgery. Neoadjuvant Therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg. 2008 Jun;247(6):1080-1; author reply 1081 [18520245.001]
  • (PMID = 17893499.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


43. Reid BJ: Early events during neoplastic progression in Barrett's esophagus. Cancer Biomark; 2010;9(1-6):307-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early events during neoplastic progression in Barrett's esophagus.
  • Barrett's esophagus is a condition in which the stratified squamous epithelium of the distal esophagus is replaced by specialized intestinal metaplasia.
  • Clinical management of Barrett's esophagus, like many other "premalignant" conditions, is characterized by overdiagnosis of benign early changes that will not cause death or suffering during the lifetime of an individual and underdiagnosis of life-threatening early disease.
  • Recent studies of a number of different types of cancer have revealed much greater genomic complexity than was previously suspected.
  • This genomic complexity could create challenges for early detection and prevention if it develops in premalignant epithelia prior to cancer.
  • Neoplastic progression unfolds in space and time, and Barrett's esophagus provides one of the best models for rapid advances, including "gold standard" cohort studies, to distinguish individuals who do and do not progress to cancer.
  • A large body of evidence accumulated over several decades implicates chromosome instability in neoplastic progression from Barrett's esophagus to esophageal adenocarcinoma.
  • Small, spatial scale studies have been used to infer the temporal order in which genomic abnormalities develop during neoplastic progression in Barrett's esophagus.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 2006 Dec;41(12):1186-96 [17287898.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e67 [17326708.001]
  • [Cites] Am J Gastroenterol. 2007 Mar;102(3):483-93; quiz 694 [17338734.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):1914-21 [17236199.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jun;46(6):532-42 [17330261.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Jul;293(1):G264-70 [17431220.001]
  • [Cites] J Mol Med (Berl). 2007 Jul;85(7):733-43 [17415542.001]
  • [Cites] Gastrointest Endosc. 2007 Sep;66(3):460-8 [17643436.001]
  • [Cites] N Engl J Med. 1992 Mar 12;326(11):737-40 [1445507.001]
  • [Cites] Gastroenterol Clin North Am. 1991 Dec;20(4):791-816 [1787014.001]
  • [Cites] Hum Pathol. 1992 May;23(5):479-82 [1568744.001]
  • [Cites] Cancer Res. 1992 May 15;52(10):2946-50 [1581911.001]
  • [Cites] Gastroenterol Clin Biol. 1991;15(10):703-10 [1816011.001]
  • [Cites] Gut. 1992 May;33(5):587-91 [1351861.001]
  • [Cites] Gut. 1992 Jun;33(6):733-7 [1624150.001]
  • [Cites] Gastroenterology. 1992 Dec;103(6):1769-76 [1360434.001]
  • [Cites] Cancer Res. 1993 Mar 15;53(6):1322-7 [8443812.001]
  • [Cites] Endoscopy. 1993 Nov;25(9):648-51 [8119224.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2292-5 [8162566.001]
  • [Cites] Gastroenterology. 1994 Jun;106(6):1589-95 [8194706.001]
  • [Cites] Stat Med. 1994 May 15;13(9):955-68 [8047747.001]
  • [Cites] Gut. 1994 Oct;35(10):1348-51 [7959183.001]
  • [Cites] Cancer. 1995 Jan 15;75(2):423-9 [7812911.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 3;92(1):151-5 [7816807.001]
  • [Cites] Br J Surg. 1994 Dec;81(12):1766-8 [7827934.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1994;59:577-83 [7587115.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):47-56 [12512029.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):776-81 [12552134.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):368-78 [11331953.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1607-19 [11375943.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1630-9 [11375945.001]
  • [Cites] Ann Thorac Surg. 2001 Aug;72(2):334-9; discussion 339-41 [11515862.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):592-8 [11522743.001]
  • [Cites] Am J Gastroenterol. 2001 Sep;96(9):2575-83 [11569678.001]
  • [Cites] Am J Gastroenterol. 2001 Oct;96(10):2839-48 [11693316.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8284-9 [11719461.001]
  • [Cites] Am J Gastroenterol. 2001 Nov;96(11):3071-83 [11721752.001]
  • [Cites] Gastrointest Endosc. 2001 Dec;54(6):682-8 [11726842.001]
  • [Cites] Neoplasia. 2002 Mar-Apr;4(2):121-8 [11896567.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1101-12 [11910360.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1128-37 [11948273.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9433-8 [12093899.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):235-56 [12424848.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Nov;14(11):1179-86 [12439111.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16226-31 [12446840.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16910-5 [12486240.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Jun;18(6):683-9 [12753151.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2560-6 [12855631.001]
  • [Cites] Gut. 2003 Aug;52(8):1081-4 [12865262.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4211-7 [12874028.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2912-9 [12912936.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):695-701 [12951588.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Am J Pathol. 1988 Apr;131(1):53-61 [3354644.001]
  • [Cites] Gastroenterology. 1989 Feb;96(2 Pt 1):355-67 [2910757.001]
  • [Cites] Lab Invest. 1989 Jan;60(1):65-71 [2911184.001]
  • [Cites] Lab Invest. 1989 Mar;60(3):418-32 [2927081.001]
  • [Cites] Stat Med. 1989 Apr;8(4):431-40 [2727467.001]
  • [Cites] Gastroenterology. 1989 Oct;97(4):815-20 [2777038.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 2;96(11):885-7; author reply 887 [15173278.001]
  • [Cites] J Pathol. 2004 Jul;203(3):780-8 [15221937.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] Oncogene. 2007 Sep 20;26(43):6332-40 [17452981.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2649-55 [18086770.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):111-7 [18199717.001]
  • [Cites] Aliment Pharmacol Ther. 2008 Feb 15;27(4):316-20 [18062791.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1303-10 [18000824.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):788-97 [18341497.001]
  • [Cites] PLoS One. 2008;3(4):e1890 [18382671.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4163-72 [18519675.001]
  • [Cites] Dig Liver Dis. 2008 Jul;40(7):510-22 [18400571.001]
  • [Cites] Gut. 2008 Aug;57(8):1041-8 [18305067.001]
  • [Cites] Am J Epidemiol. 2008 Aug 1;168(3):237-49 [18550563.001]
  • [Cites] Hum Pathol. 2008 Aug;39(8):1128-35 [18602665.001]
  • [Cites] Genome Res. 2008 Sep;18(9):1518-29 [18577705.001]
  • [Cites] Science. 2008 Sep 5;321(5894):1280-1 [18772403.001]
  • [Cites] Gut. 2008 Oct;57(10):1354-9 [18424568.001]
  • [Cites] Int J Cancer. 2008 Nov 15;123(10):2331-6 [18729198.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1801-6 [18772397.001]
  • [Cites] Dis Esophagus. 2008;21(6):529-38 [18840137.001]
  • [Cites] Mol Cancer. 2008;7:75 [18831746.001]
  • [Cites] Gastroenterology. 2008 Oct;135(4):1392-1413, 1413.e1-5 [18801365.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):6988-95 [18980994.001]
  • [Cites] PLoS One. 2008;3(11):e3809 [19043591.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Nov;1(6):413-23 [19138988.001]
  • [Cites] Nat Genet. 2009 Feb;41(2):178-86 [19151715.001]
  • [Cites] Cell Cycle. 2009 Mar 15;8(6):809-17 [19229128.001]
  • [Cites] Cancer Biomark. 2009;5(3):143-58 [19407369.001]
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3305-14 [19417022.001]
  • [Cites] Gastrointest Endosc. 1999 Dec;50(6):814-8 [10570342.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2087-95 [10601379.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):35-9 [10665910.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):555-66 [10666385.001]
  • [Cites] Cancer Causes Control. 2000 Mar;11(3):231-8 [10782657.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1702-10 [10815888.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1669-76 [10925966.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1316-21 [10944553.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):1888-93 [10950031.001]
  • [Cites] Genome Res. 2000 Aug;10(8):1126-37 [10958631.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5021-6 [11016622.001]
  • [Cites] BMJ. 2000 Nov 18;321(7271):1252-5 [11082084.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3164-70 [11306503.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Dec;38(4):302-6 [14566848.001]
  • [Cites] Mod Pathol. 2004 May;17(5):588-96 [15017433.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3414-27 [15150093.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 May;4(5):566-72 [16630761.001]
  • [Cites] Gut. 2006 Jun;55(6):764-74 [16368780.001]
  • [Cites] Oncogene. 2006 May 18;25(21):3084-92 [16407829.001]
  • [Cites] Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943 [16928254.001]
  • [Cites] Gut. 2006 Oct;55(10):1390-7 [16682429.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1935-40 [17035402.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Clin Cancer Res. 2006 Nov 15;12(22):6637-42 [17121882.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):659-65 [17255290.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):509-16 [16537709.001]
  • [Cites] Nat Genet. 2006 Apr;38(4):468-73 [16565718.001]
  • [Cites] Cancer Genet Cytogenet. 1989 Oct 15;42(2):281-6 [2790761.001]
  • [Cites] Science. 1990 Jan 5;247(4938):49-56 [2294591.001]
  • [Cites] Cancer Res. 1991 Jun 15;51(12):3075-9 [2039987.001]
  • [Cites] Surg Oncol. 1995 Jun;4(3):163-71 [7582189.001]
  • [Cites] Cancer Res. 1996 Jan 15;56(2):259-63 [8542577.001]
  • [Cites] Oncogene. 1996 May 2;12(9):1873-8 [8649847.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Gut. 2003 May;52(5):623-8 [12692043.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1116-9 [8630885.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7081-4 [8692948.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4499-502 [8813147.001]
  • [Cites] Am J Clin Pathol. 1996 Sep;106(3):298-304 [8816585.001]
  • [Cites] Gut. 1996 Jul;39(1):5-8 [8881798.001]
  • [Cites] Oncogene. 1996 Nov 7;13(9):1867-73 [8934532.001]
  • [Cites] Am J Gastroenterol. 1997 Apr;92(4):586-91 [9128304.001]
  • [Cites] Surg Oncol Clin N Am. 1997 Jul;6(3):515-31 [9210354.001]
  • [Cites] J Clin Invest. 1997 Oct 15;100(8):2133-7 [9329980.001]
  • [Cites] Oncogene. 1997 Oct 2;15(14):1653-9 [9349498.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):97-102 [9488582.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):641-51 [9708926.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):950-7 [9764589.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Oct 1;106(1):11-7 [9772903.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1381-6 [9834265.001]
  • [Cites] JAMA. 1998 Nov 25;280(20):1747-51 [9842949.001]
  • [Cites] Cytometry. 1998 Dec 15;34(6):257-63 [9879642.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Nat Genet. 1999 May;22(1):106-9 [10319873.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):965-73 [10233832.001]
  • [Cites] Gastrointest Endosc. 1999 Jul;50(1):23-6 [10385717.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1862-7 [10430093.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4784-7 [10519384.001]
  • [Cites] Surgery. 1957 Jun;41(6):881-94 [13442856.001]
  • [Cites] Semin Cancer Biol. 2005 Feb;15(1):51-60 [15613288.001]
  • [Cites] Cancer Lett. 2005 Jan 20;217(2):221-30 [15617840.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Neoplasia. 2004 Nov-Dec;6(6):751-60 [15720801.001]
  • [Cites] Am J Gastroenterol. 2005 Apr;100(4):775-83 [15784018.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):830-4 [15824152.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3146-54 [15833844.001]
  • [Cites] Oncogene. 2005 Jun 9;24(25):4138-48 [15824739.001]
  • [Cites] Int J Cancer. 2005 Sep 10;116(4):584-91 [15825175.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):488-98 [16185958.001]
  • [Cites] Gastroenterology. 2005 Oct;129(4):1274-81 [16230080.001]
  • [Cites] Neoplasia. 2005 Sep;7(9):854-61 [16229808.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):945-52 [16321762.001]
  • [Cites] J Pathol. 2006 Jan;208(1):100-7 [16278815.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Am J Gastroenterol. 2005 Dec;100(12):2616-21 [16393209.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13 [13130116.001]
  • [Cites] Am J Gastroenterol. 2003 Sep;98(9):1931-9 [14499768.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6293-300 [17975140.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Dec;26(11-12):1465-77 [17900269.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Dec;293(6):G1106-13 [17932229.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7629-33 [15492292.001]
  • [Cites] Science. 1976 Oct 1;194(4260):23-8 [959840.001]
  • [Cites] Gastroenterology. 1978 Oct;75(4):683-7 [710836.001]
  • [Cites] Arch Surg. 1983 May;118(5):543-9 [6838359.001]
  • [Cites] Gastroenterology. 1987 Jul;93(1):1-11 [3582897.001]
  • [Cites] Am J Gastroenterol. 1987 Oct;82(10):1012-5 [3661507.001]
  • [Cites] Gastroenterology. 1988 Jan;94(1):81-90 [3335302.001]
  • (PMID = 22112482.001).
  • [ISSN] 1875-8592
  • [Journal-full-title] Cancer biomarkers : section A of Disease markers
  • [ISO-abbreviation] Cancer Biomark
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA091955; United States / NCI NIH HHS / CA / P01CA91955
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS578448; NLM/ PMC4026269
  •  go-up   go-down


44. Hornick JL, Odze RD: Neoplastic precursor lesions in Barrett's esophagus. Gastroenterol Clin North Am; 2007 Dec;36(4):775-96, v
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoplastic precursor lesions in Barrett's esophagus.
  • Barrett's esophagus, currently defined as endoscopically apparent columnar metaplasia of the esophagus with histologic documentation of goblet cells, is the precursor to esophageal adenocarcinoma.
  • However, not all patients with this disorder require intensive surveillance.
  • Pathologic diagnosis and grading of dysplasia in mucosal biopsies remains the best and most widely used method of determining which patients are at highest risk for neoplastic progression.
  • Therefore, consultation with expert gastrointestinal pathologists to confirm the diagnosis of dysplasia before definitive management is highly advisable.
  • This article focuses on dysplasia in Barrett's esophagus in terms of its classification, pathologic diagnostic criteria, limitations, natural history, and treatment.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Precancerous Conditions / pathology

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17996790.001).
  • [ISSN] 0889-8553
  • [Journal-full-title] Gastroenterology clinics of North America
  • [ISO-abbreviation] Gastroenterol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 111
  •  go-up   go-down


45. Howard JM, Beddy P, Ennis D, Keogan M, Pidgeon GP, Reynolds JV: Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma. Br J Surg; 2010 Jul;97(7):1020-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma.
  • BACKGROUND: Obesity is associated with oesophageal adenocarcinoma, but mechanisms linking fat and carcinogenesis remain poorly understood.
  • METHODS: Seventy-five patients with oesophageal adenocarcinoma underwent anthropometric and radiological assessment of obesity.
  • The human oesophageal adenocarcinoma cell line OE33 was used as the calibrator sample.
  • CONCLUSION: Obesity is associated with upregulated ObR and AdipR2 expression in oesophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Esophageal Neoplasms. Esophagogastric Junction. Obesity, Abdominal / complications. Receptors, Adiponectin / metabolism. Receptors, Leptin / metabolism

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 20632267.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ADIPOR1 protein, human; 0 / ADIPOR2 protein, human; 0 / Adipokines; 0 / Receptors, Adiponectin; 0 / Receptors, Leptin
  •  go-up   go-down


46. Sobol UA, Sherman KL, Smith J, Nagda SN, Micetich K, Nickoloff BJ, Shoup MC: Sweet's syndrome with neurologic manifestations in a patient with esophageal adenocarcinoma: case report and review of the literature. Int J Dermatol; 2009 Oct;48(10):1062-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sweet's syndrome with neurologic manifestations in a patient with esophageal adenocarcinoma: case report and review of the literature.
  • METHODS: This report describes a 62-year-old man with adenocarcinoma of the esophagus who developed Sweet's syndrome and whose postoperative course was complicated by encephalitis.
  • RESULTS: A diagnosis of Sweet's syndrome with neurologic manifestations was made, and the patient was treated with oral corticosteroids.
  • CONCLUSION: Neurologic symptoms in Sweet's syndrome are infrequently reported and have not been described previously in a patient with adenocarcinoma of the esophagus.
  • [MeSH-major] Adenocarcinoma / complications. Encephalitis / etiology. Esophageal Neoplasms / complications. Sweet Syndrome / complications. Sweet Syndrome / etiology

  • MedlinePlus Health Information. consumer health - Encephalitis.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19785087.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 48
  •  go-up   go-down


47. Grotenhuis BA, Dinjens WN, Wijnhoven BP, Sonneveld P, Sacchetti A, Franken PF, van Dekken H, Tilanus HW, van Lanschot JJ, Fodde R: Barrett's oesophageal adenocarcinoma encompasses tumour-initiating cells that do not express common cancer stem cell markers. J Pathol; 2010 Aug;221(4):379-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's oesophageal adenocarcinoma encompasses tumour-initiating cells that do not express common cancer stem cell markers.
  • Accumulating evidence has suggested that tumours have a hierarchical organization in which only the cancer stem cells (CSCs) have tumour-initiating properties.
  • Several surface antigens have been employed to isolate CSCs from various malignancies, although not from oesophageal adenocarcinoma (EA).
  • We tested whether Barrett's oesophagus (BE) and EA might serve as a model for the CSC concept.
  • Accordingly, all markers were employed to sort the corresponding subpopulations of cancer cells and transplant them at low multiplicities in NOD-SCID mice.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Biomarkers, Tumor / metabolism. Esophageal Neoplasms / pathology. Neoplastic Stem Cells / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pathol. 2011 May;224(1):143-5 [21480231.001]
  • (PMID = 20549647.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


48. Cockburn MG, Wu AH, Bernstein L: Etiologic clues from the similarity of histology-specific trends in esophageal and lung cancers. Cancer Causes Control; 2005 Nov;16(9):1065-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etiologic clues from the similarity of histology-specific trends in esophageal and lung cancers.
  • OBJECTIVE: We tested whether descriptive evidence exists for differing roles of specific tobacco constituents on different histologic subtypes of esophageal cancer.
  • Esophageal adenocarcinoma incidence rates are increasing while squamous cell esophageal cancer rates are declining in Westernized countries as are the histology-specific lung counterparts.
  • Smoking is also a risk factor for esophageal cancers.
  • METHODS: We compared patterns of incidence of squamous cell cancers of the lung with those of squamous cell esophageal cancers, and incidence trends in lung adenocarcinomas with those of esophageal adenocarcinomas during the time period from 1976 to 2000 using data from the population-based Los Angeles Cancer Surveillance Program.
  • RESULTS: Rates of squamous cell esophageal cancer declined in a similar fashion to those of squamous cell lung cancer, while esophageal adenocarcinoma incidence increased at a rate similar to that of lung adenocarcinoma, in both men and women, and blacks and whites.
  • Histology-specific socio-economic gradients in lung and esophageal cancers were also strikingly similar.
  • Increases in esophageal adenocarcinoma were confined to the lower third of the esophagus.
  • CONCLUSIONS: While increases in obesity over time might explain these trends, they are also consistent with a specific effect of some constituent of tobacco smoke working through reflux disease to cause esophageal adenocarcinoma.
  • [MeSH-major] Esophageal Neoplasms / epidemiology. Esophageal Neoplasms / etiology. Lung Neoplasms / epidemiology. Lung Neoplasms / etiology. Smoking / adverse effects. Tobacco / chemistry
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / etiology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / etiology. Female. Humans. Incidence. Los Angeles / epidemiology. Male. Social Class. Socioeconomic Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16184472.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / 5P30 ES07048; United States / NCI NIH HHS / CA / CA 17054; United States / NCI NIH HHS / PC / N01-PC-35139; United States / ODCDC CDC HHS / CC / U55/CCU921930-02
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  •  go-up   go-down


49. Milano F, Jorritsma T, Rygiel AM, Bergman JJ, Sondermeijer C, Ten Brinke A, vanHam SM, Krishnadath KK: Expression pattern of immune suppressive cytokines and growth factors in oesophageal adenocarcinoma reveal a tumour immune escape-promoting microenvironment. Scand J Immunol; 2008 Dec;68(6):616-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression pattern of immune suppressive cytokines and growth factors in oesophageal adenocarcinoma reveal a tumour immune escape-promoting microenvironment.
  • Immunotherapy for solid cancers, such as oesophageal adenocarcinoma (OAC), is generally hampered by an unfavourable immunological tumour microenvironment.
  • The OAC microenvironment is characterized by a lack of cytokines and factors that normally would enhance anti-cancer responses, such as IFN-gamma and GrB, and by a high expression of several immuno-suppressive factors, such as COX-2, VEGF and IL-8.
  • [MeSH-major] Adenocarcinoma / immunology. Cyclooxygenase 2 / metabolism. Cytokines / metabolism. Esophageal Neoplasms / immunology. Tumor Escape. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19055699.001).
  • [ISSN] 1365-3083
  • [Journal-full-title] Scandinavian journal of immunology
  • [ISO-abbreviation] Scand. J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Vascular Endothelial Growth Factor A; 63231-63-0 / RNA; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


50. Brun R, Naroditsky I, Waterman M, Ben-Izhak O, Groisman G, Ilan N, Vlodavsky I: Heparanase expression by Barrett's epithelium and during esophageal carcinoma progression. Mod Pathol; 2009 Dec;22(12):1548-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heparanase expression by Barrett's epithelium and during esophageal carcinoma progression.
  • More recently, heparanase upregulation was documented in an increasing number of human carcinomas and hematological malignancies, correlating with increased tumor metastasis, vascular density, and shorter post-operative survival of cancer patients.
  • Here, we used immunohistochemical analysis to investigate heparanase expression in normal esophagus, Barrett's esophagus without dysplasia, Barrett's esophagus with low-grade dysplasia, Barrett's esophagus with high-grade dysplasia, and adenocarcinoma of the esophagus.
  • We report that heparanase expression is already induced in Barrett's epithelium without dysplasia, and is further increased during progression through distinct pathological stages, namely, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma.
  • These findings suggest that heparanase function is not limited to the process of tumor metastasis, but rather is engaged at the early stages of esophagus carcinoma initiation and progression.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19749739.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106456; United States / NCI NIH HHS / CA / R01-CA106456
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


51. Gatenby PA, Caygill CP, Ramus JR, Charlett A, Watson A: Barrett's columnar-lined oesophagus: demographic and lifestyle associations and adenocarcinoma risk. Dig Dis Sci; 2008 May;53(5):1175-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's columnar-lined oesophagus: demographic and lifestyle associations and adenocarcinoma risk.
  • OBJECTIVES: Lifestyle and demographic risk factors for the development of oesophageal adenocarcinoma developing from columnar-lined oesophagus are not well defined.
  • The associations of columnar-lined oesophagus with demographic and lifestyle factors and the development of adenocarcinoma were examined.
  • RESULTS: 5.5% of patients had prevalent adenocarcinoma (more common in males, older patients, patients diagnosed earlier in the cohort and current or recent smokers).
  • Adenocarcinoma incidence was 23 patients in 3,912 years or 0.59% per annum.
  • Only increased age at diagnosis correlated with an increased risk of incident adenocarcinoma.
  • CONCLUSIONS: Oesophageal adenocarcinoma occurs more commonly in older patients and is more frequent in males than females.
  • Once columnar-lined oesophagus had been diagnosed, there were no other demographic or lifestyle factors which were predictive of the development of incident adenocarcinoma in this cohort.
  • [MeSH-major] Adenocarcinoma / epidemiology. Barrett Esophagus / epidemiology. Esophageal Neoplasms / epidemiology. Life Style

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer Prev. 1992 Apr;1(3):275-8 [1467774.001]
  • [Cites] Gastroenterology. 2000 Apr;118(4):670-7 [10734018.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2033-6 [10445524.001]
  • [Cites] Gastrointest Endosc. 2003 Mar;57(3):311-8 [12612508.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] Am J Gastroenterol. 1998 Jun;93(6):911-5 [9647017.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2043-53 [10445526.001]
  • (PMID = 17939050.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


52. Fléjou JF: Barrett's oesophagus: from metaplasia to dysplasia and cancer. Gut; 2005 Mar;54 Suppl 1:i6-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's oesophagus: from metaplasia to dysplasia and cancer.
  • Barrett's oesophagus is a premalignant condition that predisposes to the development of oesophageal adenocarcinoma.
  • It is detected on endoscopy and confirmed histologically by the presence in the lower oesophagus of a metaplastic mucosa, the so-called specialised epithelium, which resembles incomplete intestinal metaplasia in the stomach.
  • Dysplasia, a synonym of intraepithelial neoplasia, is the only marker that can be used at the present time to delineate a population of patients at high risk of cancer.
  • [MeSH-major] Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Aneuploidy. Cell Transformation, Neoplastic / pathology. DNA, Neoplasm / analysis. Esophagus / pathology. Genes, p53 / genetics. Humans. Immunohistochemistry / methods. Mucins / analysis. Mucous Membrane / pathology. Neoplasms, Glandular and Epithelial / classification. Neoplasms, Glandular and Epithelial / pathology. Risk Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):87-94 [11145256.001]
  • [Cites] Int J Cancer. 2000 Dec 15;88(6):856-61 [11093805.001]
  • [Cites] Scand J Gastroenterol. 2000 Dec;35(12):1238-44 [11199360.001]
  • [Cites] Ann Surg. 2001 Mar;233(3):322-37 [11224619.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):368-78 [11331953.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):379-88 [11331954.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1355-62 [11374668.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1378-82 [11374671.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1607-19 [11375943.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1630-9 [11375945.001]
  • [Cites] Gut. 2001 Dec;49(6):761-6 [11709508.001]
  • [Cites] Oncogene. 2002 Jan 17;21(3):475-8 [11821959.001]
  • [Cites] Semin Diagn Pathol. 2002 Feb;19(1):12-9 [11936261.001]
  • [Cites] Mod Pathol. 2002 Jun;15(6):611-6 [12065774.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Jun;31(2):461-79, ix [12134613.001]
  • [Cites] Gut. 2002 Nov;51(5):671-6 [12377805.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2514-23 [12385432.001]
  • [Cites] Lancet. 2002 Nov 16;360(9345):1587-9 [12443613.001]
  • [Cites] Virchows Arch. 2003 Jan;442(1):18-24 [12536310.001]
  • [Cites] Gut. 2003 Apr;52(4):486-9 [12631655.001]
  • [Cites] Virchows Arch. 2003 Nov;443(5):597-601 [14508684.001]
  • [Cites] N Engl J Med. 1976 Aug 26;295(9):476-80 [940579.001]
  • [Cites] Hum Pathol. 1983 Nov;14(11):931-68 [6629368.001]
  • [Cites] J Clin Pathol. 1984 Jun;37(6):607-10 [6725608.001]
  • [Cites] J Cancer Res Clin Oncol. 1985;110(2):145-52 [4044629.001]
  • [Cites] Gastroenterology. 1986 Jun;90(6):1932-41 [2422089.001]
  • [Cites] Gut. 1986 Sep;27(9):1062-8 [3758820.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Gastroenterology. 1989 Oct;97(4):815-20 [2777038.001]
  • [Cites] Gastroenterology. 1992 Apr;102(4 Pt 1):1212-9 [1551528.001]
  • [Cites] Hum Pathol. 1992 May;23(5):475-6 [1568742.001]
  • [Cites] Gastroenterology. 1993 Jul;105(1):40-50 [8514061.001]
  • [Cites] Hum Pathol. 1994 Sep;25(9):915-9 [8088767.001]
  • [Cites] Cancer. 1995 Jan 15;75(2):423-9 [7812911.001]
  • [Cites] Gastroenterology. 1996 Feb;110(2):614-21 [8566611.001]
  • [Cites] Ann Surg. 1996 Jul;224(1):66-71 [8678620.001]
  • [Cites] J Clin Invest. 1996 Nov 1;98(9):2120-8 [8903332.001]
  • [Cites] Dig Dis Sci. 1997 Apr;42(4):697-701 [9125634.001]
  • [Cites] Am J Gastroenterol. 1997 Apr;92(4):586-91 [9128304.001]
  • [Cites] Gastroenterol Clin North Am. 1997 Sep;26(3):533-48 [9309403.001]
  • [Cites] Gastroenterol Clin North Am. 1997 Sep;26(3):599-606 [9309407.001]
  • [Cites] Dig Dis Sci. 1997 Dec;42(12):2453-62 [9440619.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1028-32 [9672324.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1033-6 [9672325.001]
  • [Cites] Cytometry. 1998 Dec 15;34(6):257-63 [9879642.001]
  • [Cites] Gastrointest Endosc. 1999 Feb;49(2):170-6 [9925694.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Mar;117(3):572-80 [10047662.001]
  • [Cites] Hum Pathol. 1999 Mar;30(3):288-94 [10088547.001]
  • [Cites] Histol Histopathol. 1999 Apr;14(2):553-9 [10212817.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):965-73 [10233832.001]
  • [Cites] Gastrointest Endosc. 1999 Jul;50(1):23-6 [10385717.001]
  • [Cites] Hum Pathol. 1999 Jul;30(7):745-52 [10414492.001]
  • [Cites] Histopathology. 1999 Dec;35(6):517-24 [10583575.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Hum Pathol. 1999 Dec;30(12):1488-95 [10667428.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1669-76 [10925966.001]
  • [Cites] Histopathology. 2000 Aug;37(2):99-107 [10931231.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):1888-93 [10950031.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):683-90 [10982762.001]
  • [Cites] Am J Gastroenterol. 2000 Dec;95(12):3383-7 [11151865.001]
  • (PMID = 15711008.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Mucins
  • [Number-of-references] 66
  • [Other-IDs] NLM/ PMC1867794
  •  go-up   go-down


53. Abnet CC, Freedman ND, Hollenbeck AR, Fraumeni JF Jr, Leitzmann M, Schatzkin A: A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma. Eur J Cancer; 2008 Feb;44(3):465-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma.
  • The incidence of oesophageal adenocarcinoma (EADC) is rapidly increasing in Western countries and obesity is thought to be a major risk factor.
  • We examined the association between BMI and EADC, gastric cardia adenocarcinoma and gastric non-cardia adenocarcinoma in a cohort of approximately 500,000 people in the United States (US).
  • We found that compared to people with a BMI of 18.5-25kg/m2, a BMI > or = 35 was associated with significantly increased risk of EADC, HR (95% CI)=2.27 (1.44-3.59) and gastric cardia adenocarcinoma 2.46 (1.60-3.80), but not gastric non-cardia adenocarcinoma 0.84 (0.50-1.42).
  • [MeSH-major] Adenocarcinoma / etiology. Attitude to Health. Body Mass Index. Cardia. Esophageal Neoplasms / etiology. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2005 Apr;16(3):285-94 [15947880.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2628-31 [16353151.001]
  • [Cites] Ann Surg. 2006 Apr;243(4):479-85 [16552198.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):872-8 [16702363.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1151-8 [16630714.001]
  • [Cites] N Engl J Med. 2006 Jun 1;354(22):2340-8 [16738270.001]
  • [Cites] Cancer Causes Control. 2006 Sep;17(7):901-9 [16841257.001]
  • [Cites] Br J Cancer. 2000 Jul;83(1):127-32 [10883680.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • [Cites] Cancer Causes Control. 2001 Oct;12(8):721-32 [11562112.001]
  • [Cites] Am J Epidemiol. 2001 Dec 15;154(12):1119-25 [11744517.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Jan;19(1):24-30 [14675239.001]
  • [Cites] J Natl Cancer Inst. 2004 Sep 15;96(18):1383-7 [15367571.001]
  • [Cites] Cancer Causes Control. 2004 Oct;15(8):837-43 [15456997.001]
  • [Cites] J Natl Cancer Inst. 1985 Feb;74(2):319-23 [3856045.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 18;87(2):104-9 [7707381.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Jul;6(7):481-5 [9232333.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):456-63 [15455378.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • (PMID = 18221867.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS42480; NLM/ PMC2350215
  •  go-up   go-down


54. Vigen C, Bernstein L, Wu AH: Occupational physical activity and risk of adenocarcinomas of the esophagus and stomach. Int J Cancer; 2006 Feb 15;118(4):1004-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occupational physical activity and risk of adenocarcinomas of the esophagus and stomach.
  • Physical activity may have a role in many cancers, but little is known about its effect on esophageal and gastric adenocarcinoma risk.
  • We investigated occupational physical activity and esophageal and gastric adenocarcinoma risk in a population-based, case-control study including 212 esophageal, 264 gastric cardia and 389 distal gastric cancer cases, and 1,330 controls in Los Angeles County.
  • Esophageal adenocarcinoma risk tended to decrease with increasing Total Activity Index (OR = 0.67, 95% CI = 0.38,1.19 for highest versus lowest quartile), but neither gastric cardia nor distal gastric cancer was associated with the Total Activity Index.
  • This inverse association held for esophageal adenocarcinoma (OR = 0.61, 95% CI = 0.38,0.99 for highest vs. lowest quartile) and modest associations were observed for gastric cardia (OR = 0.76, 95% CI = 0.49,1.18) and distal gastric cancer (OR = 0.77, 95% CI = 0.52,1.14) when based on Average Annual Activity Index before age 65 years.
  • We found a modest protective effect of Total Activity Index on esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Esophageal Neoplasms / epidemiology. Exercise. Occupations. Stomach Neoplasms / epidemiology


55. Cooper SC, El-agib A, Dar S, Mohammed I, Nightingale P, Murray IA, Cooper BT, Trudgill NJ: Endoscopic surveillance for Barrett's oesophagus: the patients' perspective. Eur J Gastroenterol Hepatol; 2009 Aug;21(8):850-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic surveillance for Barrett's oesophagus: the patients' perspective.
  • OBJECTIVE: Barrett's oesophagus (BO) is associated with the development of oesophageal adenocarcinoma and endoscopic surveillance is commonly practised.
  • Increasing TIPS score correlated with having received (r= 0.33, P <0.001) and understood (r = 0.2, P= 0.037) BO information, and negatively with the belief that endoscopic surveillance reduced oesophageal adenocarcinoma risk (r= - 0.19, P =0.025).
  • [MeSH-major] Adenocarcinoma / psychology. Anxiety / psychology. Barrett Esophagus / psychology. Depressive Disorder / psychology. Esophageal Neoplasms / psychology. Quality of Life / psychology
  • [MeSH-minor] Adult. Aged. Early Detection of Cancer. England. Esophagoscopy / psychology. Female. Humans. Male. Middle Aged. Patient Education as Topic / statistics & numerical data. Psychiatric Status Rating Scales. Surveys and Questionnaires. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anxiety.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19598328.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


56. Ogunwobi O, Mutungi G, Beales IL: Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology; 2006 Sep;147(9):4505-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation.
  • Obesity is an important risk factor for esophageal adenocarcinoma (EAC), and elevated serum leptin is characteristic of obesity.
  • We hypothesized that leptin may have biological effects in promoting esophageal adenocarcinoma and examined the effects of leptin on the OE33 Barrett's-derived EAC line.
  • These effects may contribute to the greatly increased risk of esophageal adenocarcinoma in obesity.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. JNK Mitogen-Activated Protein Kinases / metabolism. Leptin / pharmacology. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740977.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin; 0 / PTGER4 protein, human; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / Receptors, Leptin; 0 / Receptors, Prostaglandin E; 0 / Receptors, Prostaglandin E, EP4 Subtype; 0 / Recombinant Proteins; 0 / leptin receptor, human; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


57. O'Doherty MG, Abnet CC, Murray LJ, Woodside JV, Anderson LA, Brockman JD, Cantwell MM: Iron intake and markers of iron status and risk of Barrett's esophagus and esophageal adenocarcinoma. Cancer Causes Control; 2010 Dec;21(12):2269-79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iron intake and markers of iron status and risk of Barrett's esophagus and esophageal adenocarcinoma.
  • OBJECTIVE: To investigate the association between iron intake and iron status with Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC).
  • [MeSH-major] Adenocarcinoma / etiology. Barrett Esophagus / etiology. Eating. Esophageal Neoplasms / etiology. Iron, Dietary

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2007 Jul 2;97(1):118-22 [17551493.001]
  • [Cites] Public Health Nutr. 2001 Oct;4(5A):1081-8 [11820921.001]
  • [Cites] Acta Haematol. 2002;107(3):145-9 [11978935.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Jun;31(2):421-40, viii [12134611.001]
  • [Cites] Nutr Cancer. 2002;42(1):33-40 [12235648.001]
  • [Cites] Int J Cancer. 2002 Nov 20;102(3):207-11 [12397637.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):235-56 [12424848.001]
  • [Cites] Am J Clin Nutr. 2002 Dec;76(6):1375-84 [12450906.001]
  • [Cites] Circulation. 2003 Jan 28;107(3):499-511 [12551878.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3797-9 [12552996.001]
  • [Cites] Am J Gastroenterol. 2003 Jul;98(7):1627-33 [12873590.001]
  • [Cites] Am J Clin Nutr. 2003 Sep;78(3):436-40 [12936926.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1733-41 [14724826.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):403-7 [14996862.001]
  • [Cites] Gastroenterology. 1983 Dec;85(6):1354-8 [6313466.001]
  • [Cites] Am J Epidemiol. 1986 Jul;124(1):17-27 [3521261.001]
  • [Cites] Am J Clin Nutr. 1990 Feb;51(2):301-8 [2407101.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Sep-Oct;2(5):493-7 [8220096.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):160-2 [7829208.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 18;87(2):104-9 [7707381.001]
  • [Cites] J Biol Chem. 1996 Aug 30;271(35):21177-86 [8702888.001]
  • [Cites] Epidemiology. 1996 Jul;7(4):384-90 [8793364.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):300-4 [8903470.001]
  • [Cites] Eur J Clin Nutr. 1997 Jan;51 Suppl 1:S4-8 [9023471.001]
  • [Cites] Nutr Cancer. 1997;27(3):298-309 [9101561.001]
  • [Cites] Cancer Lett. 1997 Mar 19;114(1-2):215-6 [9103295.001]
  • [Cites] Am J Clin Nutr. 1998 Apr;67(4):593-4 [9537604.001]
  • [Cites] Am J Clin Nutr. 1998 Apr;67(4):722-33 [9537620.001]
  • [Cites] Carcinogenesis. 1998 Aug;19(8):1445-9 [9744541.001]
  • [Cites] Br J Cancer. 1999 Jul;80 Suppl 1:95-103 [10466767.001]
  • [Cites] Carcinogenesis. 1999 Sep;20(9):1801-8 [10469627.001]
  • [Cites] Br J Cancer. 2008 Jan 15;98(1):194-8 [18059399.001]
  • [Cites] Am J Epidemiol. 2008 Apr 1;167(7):839-46 [18218607.001]
  • [Cites] Am J Clin Nutr. 2008 May;87(5):1298-305 [18469253.001]
  • [Cites] Int J Cancer. 2008 Aug 15;123(4):852-60 [18537156.001]
  • [Cites] Anticancer Res. 2008 May-Jun;28(3B):1955-63 [18630488.001]
  • [Cites] Am J Gastroenterol. 2008 Jul;103(7):1614-23; quiz 1624 [18494834.001]
  • [Cites] Dis Model Mech. 2008 Jul-Aug;1(1):26-31 [19048049.001]
  • [Cites] Am J Gastroenterol. 2008 Dec;103(12):2997-3004 [18853987.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Oct;1(5):329-38 [19138977.001]
  • [Cites] Cancer Causes Control. 2009 Apr;20(3):279-88 [18839322.001]
  • [Cites] Helicobacter. 2008 Oct;13(5):323-40 [19250507.001]
  • [Cites] Am J Gastroenterol. 2009 Mar;104 Suppl 2:S5-9 [19262546.001]
  • [Cites] Int J Cancer. 2009 Jun 1;124(11):2671-6 [19230023.001]
  • [Cites] PLoS Med. 2007 Dec;4(12):e325 [18076279.001]
  • [Cites] Am J Gastroenterol. 2007 Oct;102(10):2323-30; quiz 2331 [17581269.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 15):2-8 [10566604.001]
  • [Cites] Carcinogenesis. 2000 Feb;21(2):257-63 [10657966.001]
  • [Cites] Am J Clin Nutr. 2000 Mar;71(3):746-51 [10702168.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):333-8 [10930368.001]
  • [Cites] Am J Clin Nutr. 2001 Jan;73(1):93-8 [11124756.001]
  • [Cites] Lancet. 2000 Dec 16;356(9247):2079-85 [11145505.001]
  • [Cites] Carcinogenesis. 2001 Jan;22(1):199-202 [11159760.001]
  • [Cites] Hepatology. 2001 Mar;33(3):647-51 [11230745.001]
  • [Cites] Eur J Cancer Prev. 2001 Aug;10(4):365-9 [11535879.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1055-62 [11588131.001]
  • [Cites] Onkologie. 2001 Dec;24(6):546-51 [11799309.001]
  • [Cites] Int J Cancer. 2008 Mar 1;122(5):1118-29 [17990321.001]
  • [Cites] J Nutr. 2005 Aug;135(8):1974-80 [16046725.001]
  • [Cites] Int J Cancer. 2005 Nov 20;117(4):643-7 [15929082.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):345-54 [16507831.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):717-25 [16614114.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4975-82 [16651456.001]
  • [Cites] World J Gastroenterol. 2007 Mar 14;13(10):1585-94 [17461453.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1306-8 [17548704.001]
  • (PMID = 20936528.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999; United States / Intramural NIH HHS / / ZIA CP000185-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Iron, Dietary
  • [Other-IDs] NLM/ NIHMS402473; NLM/ PMC3438890
  •  go-up   go-down


58. Chau I, Norman AR, Cunningham D, Oates J, Hawkins R, Iveson T, Nicolson M, Harper P, Seymour M, Hickish T: The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials. Ann Oncol; 2009 May;20(5):885-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.
  • BACKGROUND: It is unclear if differential chemotherapy effects exist on overall survival (OS), response rate (RR) and toxicity depending on primary tumour origin [oesophageal versus oesophago-gastric junction (OGJ) versus gastric adenocarcinoma].
  • This analysis used individual patient data and restricted to patients with adenocarcinoma who received one or more dose of chemotherapy.
  • RESULTS: Of the 2110 patients randomised, 1775 (84%) patients had adenocarcinoma with oesophageal (n = 485), OGJ (n = 457) and gastric (n = 833) origins.
  • The median OS was 9.5 months in oesophageal, 9.3 months in OGJ and 8.7 months in gastric cancer (P = 0.68).
  • RR was 44.1% in oesophageal, 41.1% in OGJ and 35.6% in gastric cancers (P = 0.11 and 0.27, respectively, compared with gastric cancer on multivariate analysis).
  • Toxicity composite end point occurred in 46%, 47% and 45% in oesophageal, OGJ and gastric cancers, respectively (P = 0.85 and 0.62 compared with gastric).
  • CONCLUSIONS: In our large multicentre RCT dataset, no significant differences were demonstrated on multivariate analyses in OS, RR and toxic effects among patients with advanced oesophageal, OGJ and gastric adenocarcinoma.
  • Future RCTs should not exclude oesophageal adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19164454.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


59. Starling N, Okines A, Cunningham D, Allum W, Wotherspoon A, Benson M, Thompson J, Thomas J, Brown G, Riddell A, Stavridi F, Ashley S, Oates J, Chau I: A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. Br J Cancer; 2009 Jun 2;100(11):1725-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma.
  • Preoperative cisplatin/fluorouracil is used for the treatment of localised oesophageal carcinoma.
  • Patients with stage II or III oesophageal/gastro-oesophageal junctional adenocarcinoma from one institution received 4 cycles of ECX (epirubicin 50 mg m(-2) day 1, cisplatin 60 mg m(-2) day 1, capecitabine 625 mg m(-2) b.i.d. daily) followed by surgery.
  • Although associated with a low pCR rate, survival with ECX was comparable with published studies suggesting that pCR may not correlate with satisfactory outcome from preoperative chemotherapy for localised oesophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Deoxycytidine / analogs & derivatives. Epirubicin / therapeutic use. Esophageal Neoplasms / drug therapy. Fluorouracil / analogs & derivatives. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Apr 15;88(8):1788-95 [10760753.001]
  • [Cites] N Engl J Med. 2008 Jan 3;358(1):36-46 [18172173.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):338-56 [11260097.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3058-65 [11408502.001]
  • [Cites] Br J Cancer. 2002 Apr 22;86(8):1223-9 [11953876.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):1996-2004 [11956258.001]
  • [Cites] Gastrointest Endosc. 2002 May;55(6):655-61 [11979246.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1727-33 [12049861.001]
  • [Cites] Br J Surg. 2004 Feb;91(2):199-204 [14760668.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):462-7 [8672151.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • [Cites] AJR Am J Roentgenol. 1997 Aug;169(2):485-91 [9242759.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • [Cites] J Natl Cancer Inst. 1999 Mar 17;91(6):497-8 [10088616.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Br J Cancer. 2005 Jun 6;92(11):1976-83 [15928658.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4330-7 [15781882.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4483-9 [16002838.001]
  • [Cites] Radiology. 2005 Sep;236(3):841-51 [16118165.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):659-68 [16129366.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2365-72 [16245310.001]
  • [Cites] J Surg Oncol. 2005 Dec 1;92(3):151-9 [16299786.001]
  • [Cites] Cancer. 2006 May 15;106(10):2119-27 [16607651.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(3):CD001556 [16855972.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4692-8 [16966684.001]
  • [Cites] Lancet Oncol. 2007 Mar;8(3):226-34 [17329193.001]
  • [Cites] Am J Surg. 2007 May;193(5):614-7; discussion 617 [17434367.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3719-25 [17704421.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):797-805 [17693134.001]
  • [Cites] Ann Oncol. 2007 Oct;18(10):1673-9 [17660494.001]
  • [Cites] Contemp Clin Trials. 2008 Jan;29(1):32-41 [17544337.001]
  • [Cites] BMC Med. 2004 Sep 24;2:35 [15447788.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1086-92 [18309943.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):305-13 [11208820.001]
  • (PMID = 19436301.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2695693
  •  go-up   go-down


60. Yoshida T, Shimizu Y, Kato M: Image of the month. Use of magnifying endoscopy to identify early esophageal adenocarcinoma in ectopic gastric mucosa of the cervical esophagus. Clin Gastroenterol Hepatol; 2010 Sep;8(9):e91-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image of the month. Use of magnifying endoscopy to identify early esophageal adenocarcinoma in ectopic gastric mucosa of the cervical esophagus.
  • [MeSH-major] Adenocarcinoma / diagnosis. Choristoma / pathology. Endoscopy / methods. Esophageal Neoplasms / diagnosis. Gastric Mucosa / pathology

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20347051.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Czito BG, Kelsey CR, Hurwitz HI, Willett CG, Morse MA, Blobe GC, Fernando NH, D'Amico TA, Harpole DH, Honeycutt W, Yu D, Bendell JC: A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma. Int J Radiat Oncol Biol Phys; 2007 Mar 15;67(4):1002-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma.
  • PURPOSE: Concurrent chemotherapy and radiation therapy (RT) are used to treat patients with esophageal cancer.
  • METHODS AND MATERIALS: Patients with squamous cell carcinoma or adenocarcinoma of the esophagus initially received capecitabine, carboplatin, and paclitaxel with RT (1.8 Gy daily to 50.4 Gy).
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197129.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil
  •  go-up   go-down


62. Castillo E, Lawler LP: Diagnostic radiology and nuclear medicine. J Surg Oncol; 2005 Dec 1;92(3):191-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis and accurate staging of esophageal adenocarcinoma remains one of the greatest challenges for non-invasive imaging techniques.
  • [MeSH-major] Adenocarcinoma / diagnosis. Esophageal Neoplasms / diagnosis. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16299788.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 85
  •  go-up   go-down


63. Demeester SR: Epidemiology and biology of esophageal cancer. Gastrointest Cancer Res; 2009 Mar;3(2 Suppl):S2-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology and biology of esophageal cancer.
  • In the United States and other Western countries, there has been a remarkable change in the epidemiology of esophageal cancer over the past 50 years.
  • Adenocarcinoma of the esophagus and gastroesophageal junction has replaced squamous cell as the most common type of esophageal cancer in the United States, and the incidence of esophageal adenocarcinoma is increasing faster than that of any other malignancy.
  • The increasing incidence of esophageal adenocarcinoma and a greater understanding of its underlying biology provide opportunities to devise treatment strategies that maximize survival and minimize morbidity.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Res. 2004 Mar;117(1):58-63 [15013715.001]
  • [Cites] Gut. 2003 Apr;52(4):486-9 [12631655.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):582-8 [15089886.001]
  • [Cites] Arch Surg. 2004 Jun;139(6):627-31; discussion 631-3 [15197089.001]
  • [Cites] Ann Thorac Surg. 2004 Nov;78(5):1777-82 [15511474.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Ann Surg. 2005 Oct;242(4):566-73; discussion 573-5 [16192817.001]
  • [Cites] Ann Surg Oncol. 2006 Jan;13(1):12-30 [16378161.001]
  • [Cites] Gut. 2006 Nov;55(11):1538-44 [16785284.001]
  • [Cites] J Am Coll Surg. 2006 Aug;203(2):152-61 [16864027.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Mar;133(3):738-45 [17320575.001]
  • [Cites] Gut. 2007 Nov;56(11):1503-11 [17337464.001]
  • [Cites] Eur J Cancer. 2007 Jun;43(9):1445-51 [17512189.001]
  • [Cites] J Gastrointest Surg. 2007 Nov;11(11):1384-93; discussion 1393-4 [17764019.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):665-71; discussion 671-4 [17893503.001]
  • [Cites] Gut. 2008 Mar;57(3):298-305 [17965056.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):992-1000; discussion 1000-1 [18043101.001]
  • [Cites] Cancer. 2008 Mar 15;112(6):1239-46 [18224663.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1086-92 [18309943.001]
  • [Cites] Gut. 2008 Sep;57(9):1200-6 [18460553.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Jun;135(6):1228-36 [18544359.001]
  • [Cites] Ann Surg. 2008 Aug;248(2):221-6 [18650631.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1184-7 [18695138.001]
  • [Cites] J Exp Med. 1901 Jan 15;5(4):319-32 [19866948.001]
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):462-7 [8672151.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 Dec;114(6):948-55; discussion 955-6 [9434690.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):16-23; discussion 23-5 [9869753.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 May;117(5):960-8 [10220691.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):433-8; discussion 438-40 [10493489.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):340-6 [10652424.001]
  • [Cites] Ann Intern Med. 2000 Aug 1;133(3):165-75 [10906830.001]
  • [Cites] Int J Epidemiol. 2000 Aug;29(4):645-54 [10922340.001]
  • [Cites] J Am Coll Surg. 2000 Aug;191(2):143-8 [10945357.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3202-10 [10986052.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):305-13 [11208820.001]
  • [Cites] Cancer. 2001 Mar 15;91(6):1098-104 [11267954.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1607-19 [11375943.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):581-7 [11685019.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Dec;122(6):1077-90 [11726882.001]
  • [Cites] J Am Coll Surg. 2002 Jan;194(1):28-36 [11803954.001]
  • [Cites] Gut. 2002 Mar;50(3):368-72 [11839716.001]
  • [Cites] Surg Endosc. 2003 Jan;17(1):43-8 [12364989.001]
  • [Cites] Cancer. 2002 Nov 15;95(10):2096-102 [12412162.001]
  • [Cites] Gut. 2004 May;53(5):634-40 [15082579.001]
  • (PMID = 19461918.001).
  • [ISSN] 1934-7820
  • [Journal-full-title] Gastrointestinal cancer research : GCR
  • [ISO-abbreviation] Gastrointest Cancer Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2684731
  •  go-up   go-down


64. Steffen A, Schulze MB, Pischon T, Dietrich T, Molina E, Chirlaque MD, Barricarte A, Amiano P, Quirós JR, Tumino R, Mattiello A, Palli D, Vineis P, Agnoli C, Misirli G, Boffetta P, Kaaks R, Rohrmann S, Bueno-de-Mesquita HB, Peeters PH, May AM, Spencer EA, Allen NE, Bingham S, Tjønneland A, Halkjaer J, Overvad K, Stegger J, Manjer J, Lindkvist B, Hallmanns G, Stenling R, Lund E, Riboli E, Gonzalez CA, Boeing H: Anthropometry and esophageal cancer risk in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev; 2009 Jul;18(7):2079-89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anthropometry and esophageal cancer risk in the European prospective investigation into cancer and nutrition.
  • BACKGROUND: Increasing evidence suggests that general obesity [measured by body mass index (BMI)] is positively associated with risk of esophageal adenocarcinoma (EAC).
  • In contrast, previous studies have shown inverse relations with esophageal squamous cell carcinoma (ESCC).
  • However, it is still unclear whether body fat distribution, particularly abdominal obesity, is associated with each type of esophageal cancer.
  • METHODS: We applied multivariable adjusted Cox proportional hazards regression to investigate the association between anthropometric measures and risk of EAC and ESCC among 346,554 men and women participating in the European Prospective Investigation into Cancer and Nutrition.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Squamous Cell / epidemiology. Esophageal Neoplasms / epidemiology. Obesity / epidemiology

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19567501.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United Kingdom / British Heart Foundation / / ; United Kingdom / Cancer Research UK / / ; United Kingdom / Department of Health / / ; United Kingdom / Medical Research Council / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


65. Gottrand F, Sfeir R, Coopman S, Deschildre A, Michaud L: [Outcome of children with repaired oesophageal atresia]. Arch Pediatr; 2008 Dec;15(12):1837-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Outcome of children with repaired oesophageal atresia].
  • [Transliterated title] Atrésie de l'oesophage : devenir des enfants opérés.
  • Although initial prognosis of oesophageal atresia is nowadays excellent with more than 95% of survival, the long-term complications are frequent.
  • A gastro-oesophageal reflux is found in 26 to 75% of the cases, responsible for peptic oesophagitis, anastomotic stenosis and Barrett's oesophagus, risk factor of adenocarcinoma of the oesophagus.
  • Even if the current prognosis of oesophageal atresia is good altogether, the frequency of the complications (digestive, respiratory, nutritional, orthopaedic) far from the initial intervention, and the necessity of a surveillance of the secondary oesophageal damages, justifies a systematic and multidisciplinary follow-up until adulthood.
  • [MeSH-major] Esophageal Atresia / surgery. Postoperative Complications
  • [MeSH-minor] Adolescent. Adult. Age Factors. Catheterization. Child. Child, Preschool. Deglutition Disorders / etiology. Esophageal Stenosis / diagnosis. Esophageal Stenosis / therapy. Esophagoscopy. Follow-Up Studies. Gastroesophageal Reflux / etiology. Humans. Infant. Prognosis. Quality of Life. Time Factors. Tracheoesophageal Fistula / etiology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Pediatr. 2010 Mar;17(3):300-1 [20034771.001]
  • (PMID = 18996685.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


66. Dughera L, Navino M, Cassolino P, Pellicano R: The diagnosis of gastroesophageal reflux disease. Minerva Gastroenterol Dietol; 2007 Jun;53(2):143-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnosis of gastroesophageal reflux disease.
  • Gastroesophageal reflux disease (GERD) is known to cause erosive esophagitis, Barrett esophagus and has been linked to the development of adenocarcinoma of the esophagus.
  • Currently, endoscopy is the main clinical tool for visualizing esophageal lesions, but the majority of GERD patients do not have endoscopic visible lesions and other methods are required.
  • Ambulatory esophageal pH monitoring is the gold standard in diagnosing GERD, since it measures distal esophageal acid exposure and demonstrates the relationship between symptoms and acid reflux.
  • [MeSH-major] Gastroesophageal Reflux / diagnosis
  • [MeSH-minor] Algorithms. Esophageal pH Monitoring. Esophagoscopy. Humans. Proton Pump Inhibitors

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17557042.001).
  • [ISSN] 1121-421X
  • [Journal-full-title] Minerva gastroenterologica e dietologica
  • [ISO-abbreviation] Minerva Gastroenterol Dietol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Proton Pump Inhibitors
  • [Number-of-references] 25
  •  go-up   go-down


67. Siewert JR, Feith M, Stein HJ: Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol; 2005 Jun 1;90(3):139-46; discussion 146
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification.
  • A topographic-anatomic subclassification of adenocarcinomas of the esophago-gastric junction (AEG) in distal esophageal adenocarcinoma (AEG Type I), true carcinoma of the cardia (AEG Type II), and subcardial gastric cancer (AEG Type III) was introduced in 1987 and is now increasingly accepted and used worldwide.
  • [MeSH-major] Adenocarcinoma / classification. Cardia. Esophageal Neoplasms / classification. Esophagogastric Junction. Stomach Neoplasms / classification

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 15895452.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


68. Horváth OP: [Surgical treatment for early Barrett cancer]. Magy Seb; 2009 Apr;62(2):51-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment for early Barrett cancer].
  • Adenocarcinomas in Barrett's oesophagus are more commonly diagnosed at an early stage due to effective surveillance programmes.
  • Subtotal oesophagectomy with extended lymphadenectomy is considered the best curative treatment for patients with early adenocarcinoma of the oesophagus.
  • [MeSH-major] Barrett Esophagus / diagnosis. Barrett Esophagus / surgery. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / surgery. Esophagectomy / methods. Lymph Node Excision
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Early Detection of Cancer. Esophagoscopy. Humans. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Recurrence, Local / prevention & control. Quality of Life. Sentinel Lymph Node Biopsy. Survival Rate. Vagus Nerve / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19386564.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Number-of-references] 56
  •  go-up   go-down


69. Li Y, Sun DL, Duan YN, Zhang XJ, Wang N, Zhou RM, Chen ZF, Wang SJ: Association of functional polymorphisms in MMPs genes with gastric cardia adenocarcinoma and esophageal squamous cell carcinoma in high incidence region of North China. Mol Biol Rep; 2010 Jan;37(1):197-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of functional polymorphisms in MMPs genes with gastric cardia adenocarcinoma and esophageal squamous cell carcinoma in high incidence region of North China.
  • The aim of the present study was to investigate the association of single nucleotide polymorphisms (SNPs) in matrix metalloproteinase (MMPs) with the risk of gastric cardia adenocarcinoma (GCA) and esophageal squamous cell carcinoma (ESCC).
  • [MeSH-major] Esophageal Neoplasms / epidemiology. Esophageal Neoplasms / genetics. Genetic Predisposition to Disease. Matrix Metalloproteinases / genetics. Polymorphism, Single Nucleotide / genetics. Stomach Neoplasms / epidemiology. Stomach Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / epidemiology. Adenocarcinoma / genetics. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / genetics. Case-Control Studies. China / epidemiology. Female. Gene Frequency / genetics. Haplotypes / genetics. Humans. Incidence. Male. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Epidemiol. 2000 Aug;29(4):645-54 [10922340.001]
  • [Cites] Carcinogenesis. 2005 Jun;26(6):1117-21 [15731163.001]
  • [Cites] J Biol Chem. 2001 Mar 9;276(10):7549-58 [11114309.001]
  • [Cites] Matrix Biol. 2002 Oct;21(6):487-98 [12392760.001]
  • [Cites] Circ Res. 2000 May 12;86(9):998-1003 [10807873.001]
  • [Cites] Br Heart J. 1995 Mar;73(3):209-15 [7727178.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7825-9 [11691799.001]
  • [Cites] Lung Cancer. 2007 May;56(2):273-80 [17208328.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7622-8 [15492291.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5321-5 [9850057.001]
  • [Cites] Carcinogenesis. 2004 Dec;25(12):2519-24 [15319302.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2614-20 [17473191.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2001 Nov;21(11):1834-9 [11701474.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3820-3 [12473595.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Carcinogenesis. 2006 May;27(5):1024-9 [16311244.001]
  • [Cites] Breast Cancer Res Treat. 2004 Dec;88(3):197-204 [15609121.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Gynecol Obstet Invest. 2008;65(1):68-72 [17851253.001]
  • [Cites] World J Gastroenterol. 2005 Apr 28;11(16):2385-9 [15832405.001]
  • [Cites] J Oral Pathol Med. 2004 Aug;33(7):405-9 [15250832.001]
  • [Cites] FEBS Lett. 1996 Feb 12;380(1-2):17-20 [8603731.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1748-53 [15930031.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3987-90 [12873995.001]
  • [Cites] Semin Cancer Biol. 2000 Dec;10(6):415-33 [11170864.001]
  • [Cites] Biochem Genet. 2008 Apr;46(3-4):137-44 [18210196.001]
  • (PMID = 19562509.001).
  • [ISSN] 1573-4978
  • [Journal-full-title] Molecular biology reports
  • [ISO-abbreviation] Mol. Biol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


70. Hao Y, Triadafilopoulos G, Sahbaie P, Young HS, Omary MB, Lowe AW: Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma. Gastroenterology; 2006 Sep;131(3):925-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma.
  • BACKGROUND & AIMS: Barrett's esophagus is a precursor of esophageal adenocarcinoma.
  • DNA microarrays that enable a genome-wide assessment of gene expression enhance the identification of specific genes as well as gene expression patterns that are expressed by Barrett's esophagus and adenocarcinoma compared with normal tissues.
  • Barrett's esophagus length has also been identified as a risk factor for progression to adenocarcinoma, but whether there are intrinsic biological differences between short-segment and long-segment Barrett's esophagus can be explored with microarrays.
  • METHODS: Gene expression profiles for endoscopically obtained biopsy specimens of Barrett's esophagus or esophageal adenocarcinoma and associated normal esophagus and duodenum were identified for 17 patients using DNA microarrays.
  • Barrett's esophagus and esophageal adenocarcinoma express a unique set of stromal genes that is distinct from normal tissues but similar to other cancers.
  • Adenocarcinoma also showed lower and higher expression for many genes compared with Barrett's esophagus.
  • No difference in gene expression was found between short-segment and long-segment Barrett's esophagus.
  • Stromal gene expression in Barrett's esophagus and adenocarcinoma is similar, indicating that these changes precede malignant transformation.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7127-36 [16103062.001]
  • [Cites] Genomics. 2000 May 1;65(3):299-302 [10857754.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Nucleic Acids Res. 2001 Jan 1;29(1):152-5 [11125075.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):91-9 [11786403.001]
  • [Cites] Oncogene. 2002 Jan 17;21(3):475-8 [11821959.001]
  • [Cites] Nucleic Acids Res. 2002 May 1;30(9):e36 [11972351.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 1;31(1):219-23 [12519986.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):579-85 [12592373.001]
  • [Cites] Ai Zheng. 2003 Feb;22(2):123-7 [12600283.001]
  • [Cites] Exp Cell Res. 2003 Nov 1;290(2):402-13 [14567997.001]
  • [Cites] Ann Thorac Surg. 2004 Mar;77(3):1008-15 [14992916.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;119(8):441-9 [8509434.001]
  • [Cites] Br J Cancer. 1997;75(2):258-63 [9010035.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8703-8 [9671742.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Oct 9;251(1):111-6 [9790916.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Gastroenterology. 1999 Feb;116(2):277-85 [9922307.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):595-603 [10027336.001]
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):390-9 [15725809.001]
  • [Cites] Int J Cancer. 2005 May 10;114(6):942-9 [15645429.001]
  • [Cites] PLoS Biol. 2005 Jun;3(6):e187 [15869330.001]
  • [Cites] Cancer Cell. 2005 Jun;7(6):499-500 [15950897.001]
  • [Cites] J Neurochem. 2005 Jul;94(2):520-30 [15998302.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):227-35 [10700174.001]
  • (PMID = 16952561.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK056339; United States / NIDDK NIH HHS / DK / R01 DK063624; United States / NIDDK NIH HHS / DK / P30 DK56339; United States / NIDDK NIH HHS / DK / R01 DK 063624
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / Chondroitin Sulfate Proteoglycans; 0 / Cspg2 protein, mouse; 0 / DNA, Neoplasm; 0 / Lectins, C-Type; 0 / POSTN protein, human; 0 / VCAN protein, human; 126968-45-4 / Versicans; 9007-34-5 / Collagen
  • [Other-IDs] NLM/ NIHMS12359; NLM/ PMC2575112
  •  go-up   go-down


71. Steven MJ, Fyfe AH, Raine PA, Watt I: Esophageal adenocarcinoma: a long-term complication of congenital diaphragmatic hernia? J Pediatr Surg; 2007 Jul;42(7):E1-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophageal adenocarcinoma: a long-term complication of congenital diaphragmatic hernia?
  • A 22-year-old man presented with a lower esophageal adenocarcinoma having been treated for a left-sided congenital diaphragmatic hernia (CDH) as a neonate.
  • We review the known long-term sequelae of CDH, possible theories for the occurrence of adenocarcinoma, and its implications for follow-up of patients with CDH.
  • [MeSH-major] Adenocarcinoma / etiology. Esophageal Neoplasms / etiology. Hernia, Diaphragmatic / complications
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Esophagoscopy. Humans. Male. Palliative Care. Tomography, X-Ray Computed


72. Beales IL, Ogunwobi OO: Leptin synergistically enhances the anti-apoptotic and growth-promoting effects of acid in OE33 oesophageal adenocarcinoma cells in culture. Mol Cell Endocrinol; 2007 Aug 15;274(1-2):60-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptin synergistically enhances the anti-apoptotic and growth-promoting effects of acid in OE33 oesophageal adenocarcinoma cells in culture.
  • Obesity and gastro-oesophageal reflux are the main predisposing factors for oesophageal adenocarcinoma.
  • We have examined the effects of transient acid exposure and leptin on OE33 oesophageal adenocarcinoma cells.
  • The combination of increased circulating leptin levels in obesity and transient reflux of gastric acid may promote oesophageal carcinogenesis by increasing proliferation and inhibiting apoptosis.
  • [MeSH-major] Acids / metabolism. Adenocarcinoma / metabolism. Esophageal Neoplasms / metabolism. Leptin / metabolism


73. Lerut T, Decker G, Coosemans W, De Leyn P, Decaluwé H, Nafteux P, Van Raemdonck D: Quality indicators of surgery for adenocarcinoma of the esophagus and gastroesophageal junction. Recent Results Cancer Res; 2010;182:127-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality indicators of surgery for adenocarcinoma of the esophagus and gastroesophageal junction.
  • Surgical treatment of adenocarcinoma of the esophagus and gastroesophageal junction is complex and challenging.
  • As a result there is disagreement on the selection of patients for surgery, type of surgical approach in particular in relation to the extent of lymph node dissection as well as the extent of esophageal and/or gastric resection.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagogastric Junction. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676877.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


74. Struijs B, de Bree R, van Groeningen CJ, Mooi WJ, Leemans CR: Tonsillar metastasis of oesophageal adenocarcinoma. Eur Arch Otorhinolaryngol; 2008 Jan;265(1):127-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tonsillar metastasis of oesophageal adenocarcinoma.
  • Tonsillar metastasis of adenocarcinoma of the oesophagus has not been reported previously.
  • We report a case of a 57-year-old male with a primary adenocarcinoma of the distal esophagus with a metastasis in the right palatine tonsil.
  • [MeSH-major] Adenocarcinoma / secondary. Esophageal Neoplasms / pathology. Tonsillar Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Oral Patol Oral Cir Bucal. 2005 May-Jul;10(3):252-7 [15876970.001]
  • [Cites] World J Surg. 2003 Sep;27(9):1052-7 [12917758.001]
  • [Cites] Z Laryngol Rhinol Otol. 1966 Jun;45(6):389-94 [5985937.001]
  • [Cites] Otolaryngol Clin North Am. 1979 Feb;12(1):29-43 [220581.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1979 Mar-Apr;88(2 Pt 1):235-40 [443718.001]
  • [Cites] Head Neck. 1992 Jan-Feb;14(1):55-7 [1624294.001]
  • [Cites] J Natl Cancer Inst. 1996 Apr 17;88(8):530-5 [8606381.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):328-30 [11373114.001]
  • [Cites] J Laryngol Otol. 1996 Mar;110(3):291-3 [8730375.001]
  • (PMID = 17657505.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2099162
  •  go-up   go-down


75. Kaijser M, Akre O, Cnattingius S, Ekbom A: Preterm birth, low birth weight, and risk for esophageal adenocarcinoma. Gastroenterology; 2005 Mar;128(3):607-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preterm birth, low birth weight, and risk for esophageal adenocarcinoma.
  • BACKGROUND & AIMS: Gastroesophageal reflux is common among preterm infants and those who are small for gestational age, and it is a strong risk factor for adenocarcinoma of the esophagus.
  • METHODS: In a cohort of 3364 individuals born preterm and/or small for gestational age between 1925 and 1949, we assessed the long-term risk for esophageal cancer.
  • RESULTS: The standardized incidence rate ratio for esophageal adenocarcinoma was increased more than 7-fold in the cohort (standardized incidence rate ratio, 7.27; 95% confidence interval, 1.98-18.62), and a birth weight <2000 g was associated with a more than 11-fold increase in risk (standardized incidence rate ratio, 11.5; 95% confidence interval, 1.39-41.5).
  • [MeSH-major] Adenocarcinoma / etiology. Esophageal Neoplasms / etiology. Infant, Low Birth Weight. Premature Birth / complications

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15765396.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


76. Colleypriest BJ, Palmer RM, Ward SG, Tosh D: Cdx genes, inflammation and the pathogenesis of Barrett's metaplasia. Trends Mol Med; 2009 Jul;15(7):313-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Perhaps one of the best-known examples of metaplasia is Barrett's metaplasia (BM), a pathological condition in which the distal oesophageal epithelium switches from stratified squamous to intestinal-type columnar epithelium.
  • BM predisposes to oesophageal adenocarcinoma and is the consequence of long-term acid bile reflux.
  • The incidence of BM and oesophageal adenocarcinoma has risen dramatically in recent years.
  • A key event in the pathogenesis of BM is the induction of oesophageal CDX2 expression.
  • Importantly, recent data reveal the molecular mechanisms that link inflammation in the development of Barrett's metaplasia, CDX2 and the progression to cancer.
  • [MeSH-major] Barrett Esophagus / immunology. Barrett Esophagus / pathology. Homeodomain Proteins / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19564133.001).
  • [ISSN] 1471-499X
  • [Journal-full-title] Trends in molecular medicine
  • [ISO-abbreviation] Trends Mol Med
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0300415; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDX1 protein, human; 0 / CDX2 Transcription Factor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins
  • [Number-of-references] 101
  •  go-up   go-down


77. Figueroa JD, Terry MB, Gammon MD, Vaughan TL, Risch HA, Zhang FF, Kleiner DE, Bennett WP, Howe CL, Dubrow R, Mayne ST, Fraumeni JF Jr, Chow WH: Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression. Cancer Causes Control; 2009 Apr;20(3):361-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression.
  • A number of risk factors for esophageal and gastric cancers have emerged, yet little is known whether risk factors map to molecular tumor markers such as overexpression of the tumor suppressor TP53.
  • Using a US multicenter, population-based case-control study (170 cases of esophageal adenocarcinomas, 147 gastric cardia adenocarcinomas, 220 non-cardia gastric adenocarcinomas, and 112 esophageal squamous cell carcinomas), we examined whether the risk associated with cigarette smoking, body mass index (BMI), gastroesophageal reflux disease (GERD), and non-steroidal anti-inflammatory drug (NSAID) use varied by P53 overexpression.
  • The proportion of cases overexpressing P53 by tumor subtype was 72% for esophageal adenocarcinoma, 69% for gastric cardia adenocarcinoma, 52% for non-cardia gastric adenocarcinoma, and 67% for esophageal squamous cell carcinoma.
  • For non-cardia gastric cancer however, an association with cigarette smoking was suggested for tumors that do not overexpress P53, whereas larger BMI was related to adenocarcinomas that overexpress P53 versus no overexpression.
  • Overall, this study did not find a clear relationship between P53 protein overexpression and the known risk factors for subtypes of esophageal and gastric cancers.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] Vojnosanit Pregl. 2005 Dec;62(12):879-85 [16375215.001]
  • [Cites] Nature. 1991 Jun 6;351(6326):453-6 [2046748.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2914-8 [8187077.001]
  • [Cites] Carcinogenesis. 1995 May;16(5):993-1002 [7767998.001]
  • [Cites] Pathol Res Pract. 1994 Dec;190(12):1141-8 [7540752.001]
  • [Cites] Int J Cancer. 1996 Jun 21;69(3):225-35 [8682592.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):425-32 [9028350.001]
  • [Cites] Cancer Causes Control. 2000 Mar;11(3):231-8 [10782657.001]
  • [Cites] Mod Pathol. 2001 May;14(5):397-403 [11353048.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):233-40 [11902578.001]
  • [Cites] Oncology. 2002;62(2):175-9 [11914604.001]
  • [Cites] Hum Mutat. 2002 Jun;19(6):607-14 [12007217.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):745-52 [12163328.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):47-56 [12512029.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1729-35 [14583777.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):34-9 [14744730.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1561-9 [14996709.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):450-64 [15297938.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Oct;6(10):779-82 [9332759.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Dec;6(12):1065-9 [9419404.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Br J Cancer. 1998;77(2):277-86 [9460999.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):97-102 [9488582.001]
  • [Cites] Carcinogenesis. 1999 Apr;20(4):591-7 [10223186.001]
  • [Cites] J Pathol. 1999 Jan;187(1):8-18 [10341702.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Ann Surg. 2005 Jan;241(1):63-8 [15621992.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Mar;3(3):225-30 [15765441.001]
  • [Cites] Cancer Causes Control. 2005 Apr;16(3):285-94 [15947880.001]
  • [Cites] Ann Intern Med. 2005 Aug 2;143(3):199-211 [16061918.001]
  • [Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]
  • (PMID = 18989634.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] None / None / / U01 CA057923-03; United States / NCI NIH HHS / CA / U01 CA057949; United States / NCI NIH HHS / CA / U01 CA057983; None / None / / U01 CA057983-03; United States / Intramural NIH HHS / / Z01 CP010136-12; United States / NCI NIH HHS / CA / U01 CA057923; United States / NCI NIH HHS / CA / U01 CA 57923; United States / NCI NIH HHS / CA / U01 CA057949-03; United States / NCI NIH HHS / CA / U01 CA057923-03; United States / NCI NIH HHS / CA / U01 CA057983-03; United States / NCI NIH HHS / CA / U01 CA 57983; United States / NCI NIH HHS / CA / U01 CA 57049; None / None / / U01 CA057949-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS100106; NLM/ PMC2726999
  •  go-up   go-down


78. Cook MB, Greenwood DC, Hardie LJ, Wild CP, Forman D: A systematic review and meta-analysis of the risk of increasing adiposity on Barrett's esophagus. Am J Gastroenterol; 2008 Feb;103(2):292-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A systematic review and meta-analysis of the risk of increasing adiposity on Barrett's esophagus.
  • OBJECTIVES: Esophageal adenocarcinoma and its precursor lesion, Barrett's esophagus, are increasing in incidence in western populations.
  • Gastroesophageal reflux disease (GERD) and high body mass index (BMI) are known risk factors, but it is unclear whether BMI mediates its risk on Barrett's esophagus independently.
  • This systematic review and meta-analysis investigated whether increasing BMI is associated with Barrett's esophagus as compared to general population and GERD controls.
  • Studies to be included were required to present "current" BMI data for consecutively recruited Barrett's esophagus patients and appropriate comparison arms with a minimum number of 30 subjects in each.
  • Nine studies comparing the BMI of the Barrett's esophagus and GERD groups produced a pooled odds ratio (OR) of 0.99 per kg/m2 (95% confidence interval [CI] 0.97-1.01, I2= 52%), while the pooled estimate of three studies comparing Barrett's esophagus with general population controls was 1.02 per kg/m2 (95% CI 1.01-1.04, I2= 0%).
  • CONCLUSIONS: Increasing adiposity is only an indirect risk factor of Barrett's esophagus through the precursor lesion of GERD.
  • Hence, BMI status has no predictive value with respect to GERD patients and their risk of progression to Barrett's esophagus.
  • [MeSH-major] Adipose Tissue. Barrett Esophagus / epidemiology. Barrett Esophagus / etiology. Body Mass Index. Gastroesophageal Reflux / complications

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - GERD.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Gastroenterol. 2008 Feb;103(2):301-3 [18289199.001]
  • [CommentIn] Am J Gastroenterol. 2008 May;103(5):1316-7 [18477363.001]
  • (PMID = 17986313.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Number-of-references] 55
  •  go-up   go-down


79. Bani-Hani KE, Bani-Hani BK: Columnar lined (Barrett's) esophagus: future perspectives. J Gastroenterol Hepatol; 2008 Feb;23(2):178-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Columnar lined (Barrett's) esophagus: future perspectives.
  • Columnar lined esophagus (CLE) or Barrett's esophagus is the precursor for esophageal adenocarcinoma.
  • The rapid increase in incidence of CLE and adenocarcinoma raises serious concerns that the current management of gastroesophageal reflux disease (GERD) needs reassessment.
  • The benefit of surveillance strategies remains unproven and the ideal endoscopic frequency, protocols and markers of cancer risk are unknown.
  • Dysplasia may not provide the gold standard marker of cancer risk because of some inherited problems.
  • To overcome the limitations of histological markers, many other markers of cancer risk needs to be developed and validated.
  • The key question as to whether cancer risk is actually reduced by the new ablation modalities remains unanswered.
  • [MeSH-major] Barrett Esophagus
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / etiology. Adenocarcinoma / prevention & control. Biomarkers. Diagnosis, Differential. Esophageal Neoplasms / epidemiology. Esophageal Neoplasms / etiology. Esophageal Neoplasms / prevention & control. Gastroenterology / trends. Gastroesophageal Reflux / complications. Gastroesophageal Reflux / diagnosis. Humans. Incidence. Intestines / pathology. Metaplasia. Precancerous Conditions / complications. Precancerous Conditions / diagnosis. Precancerous Conditions / epidemiology. Precancerous Conditions / therapy. Risk Factors

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17854426.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers
  • [Number-of-references] 122
  •  go-up   go-down


80. Wilkins T, Gillies RA: Office-based unsedated ultrathin esophagoscopy in a primary care setting. Ann Fam Med; 2005 Mar-Apr;3(2):126-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Gastroesophageal reflux disease is common and with time may be complicated by Barrett's esophagus and esophageal adenocarcinoma.
  • Upper gastrointestinal endoscopy, including esophagoscopy, is the procedure of choice to diagnose Barrett's esophagus and other esophageal disease.
  • Barrett's esophagus was diagnosed in 5.7% (n = 3) of the patients.
  • UUE may be an efficient method of examining the distal esophagus.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2000 Jun;51(6):786-9 [10840336.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Mar;105(3):383-7; discussion 387-8 [8445916.001]
  • [Cites] Curr Probl Cancer. 2000 Nov-Dec;24(6):297-373 [11198836.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Sep;125(3):170-5 [11555750.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Dec;125(6):588-9 [11743456.001]
  • [Cites] Gastrointest Endosc. 2002 Apr;55(4):484-7 [11923758.001]
  • [Cites] Gastrointest Endosc. 2002 May;55(6):620-3 [11979240.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Gastrointest Endosc. 2002 Aug;56(2):180-9 [12145594.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1888-95 [12190150.001]
  • [Cites] Gastrointest Endosc. 2002 Oct;56(4):472-8 [12297760.001]
  • [Cites] Am J Med. 2002 Oct 15;113(6):499-505 [12427500.001]
  • [Cites] Laryngoscope. 2002 Dec;112(12):2242-3 [12461347.001]
  • [Cites] Gastrointest Endosc. 2003 Mar;57(3):300-4 [12612506.001]
  • [Cites] Gastrointest Endosc. 2003 Mar;57(3):305-10 [12612507.001]
  • [Cites] Gastrointest Endosc. 2003 Mar;57(3):311-8 [12612508.001]
  • [Cites] Am J Gastroenterol. 2003 Sep;98(9):1931-9 [14499768.001]
  • [Cites] Am J Gastroenterol. 2003 Nov;98(11):2342-4 [14638331.001]
  • [Cites] Am J Gastroenterol. 2003 Nov;98(11):2383-9 [14638337.001]
  • [Cites] Gastrointest Endosc. 2004 Mar;59(3):349-54 [14997130.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] J Fam Pract. 1982 Apr;14(4):757, 762-3 passim [7069393.001]
  • [Cites] Gastrointest Endosc. 1982 Nov;28(4):233-6 [7173573.001]
  • [Cites] N Engl J Med. 1986 Aug 7;315(6):362-71 [2874485.001]
  • [Cites] Gastroenterology. 1990 Oct;99(4):918-22 [2394347.001]
  • [Cites] N Engl J Med. 1994 Sep 8;331(10):656-60 [8052276.001]
  • [Cites] Gastroenterology. 1995 Mar;108(3):697-704 [7875472.001]
  • [Cites] Endoscopy. 1996 Mar;28(3):277-82 [8781790.001]
  • [Cites] Endoscopy. 2000 Dec;32(12):971-3 [11147947.001]
  • (PMID = 15798038.001).
  • [ISSN] 1544-1717
  • [Journal-full-title] Annals of family medicine
  • [ISO-abbreviation] Ann Fam Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1466858
  •  go-up   go-down


81. Reid BJ, Li X, Galipeau PC, Vaughan TL: Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer; 2010 Feb;10(2):87-101
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis.
  • The public health importance of Barrett's oesophagus lies in its association with oesophageal adenocarcinoma.
  • The incidence of oesophageal adenocarcinoma has risen at an alarming rate over the past four decades in many regions of the Western world, and there are indications that the incidence of this disease is on the rise in Asian populations in which it has been rare.
  • Much has been learned of host and environmental risk factors that affect the incidence of oesophageal adenocarcinoma, and data indicate that patients with Barrett's oesophagus rarely develop oesophageal adenocarcinoma.
  • Given that 95% of oesophageal adenocarcinomas arise in individuals without a prior diagnosis of Barrett's oesophagus, what strategies can be used to reduce late diagnosis of oesophageal adenocarcinoma?

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3305-14 [19417022.001]
  • [Cites] N Engl J Med. 2009 May 28;360(22):2277-88 [19474425.001]
  • [Cites] Am J Gastroenterol. 2009 Jun;104(6):1356-62 [19491849.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):2079-89 [19567501.001]
  • [Cites] Histopathology. 2009 Jun;54(7):814-9 [19635100.001]
  • [Cites] Am J Gastroenterol. 2009 Sep;104(9):2153-60 [19584833.001]
  • [Cites] BMC Fam Pract. 2009;10:59 [19706198.001]
  • [Cites] Nat Rev Cancer. 2009 Oct;9(10):701-13 [19693097.001]
  • [Cites] Gut. 2009 Nov;58(11):1451-9 [19651633.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Dec;7(12):1299-304 [19523538.001]
  • [Cites] Dis Esophagus. 2009;22(8):676-81 [19222529.001]
  • [Cites] Biomarkers. 2006 Nov-Dec;11(6):547-61 [17056474.001]
  • [Cites] Am J Gastroenterol. 2006 Nov;101(11):2619-28 [16952280.001]
  • [Cites] Gut. 2006 Dec;55(12):1810-20 [17124160.001]
  • [Cites] Semin Radiat Oncol. 2007 Jan;17(1):2-9 [17185192.001]
  • [Cites] Scand J Gastroenterol. 2007 Jan;42(1):23-7 [17190758.001]
  • [Cites] Am J Gastroenterol. 2007 Jan;102(1):10-20 [17266684.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e67 [17326708.001]
  • [Cites] Am J Gastroenterol. 2007 Mar;102(3):483-93; quiz 694 [17338734.001]
  • [Cites] J Natl Cancer Inst. 2007 Apr 4;99(7):545-57 [17405999.001]
  • [Cites] World J Gastroenterol. 2007 Mar 14;13(10):1585-94 [17461453.001]
  • [Cites] Cancer Causes Control. 2007 Nov;18(9):1039-46 [17665311.001]
  • [Cites] Cancer Detect Prev. 2007;31(3):233-6 [17646057.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1643-58 [17674367.001]
  • [Cites] Gastrointest Endosc. 2007 Sep;66(3):460-8 [17643436.001]
  • [Cites] Int J Pediatr Obes. 2006;1(2):109-13 [17907323.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2090-6 [17890521.001]
  • [Cites] Am J Gastroenterol. 2007 Nov;102(11):2373-9 [17581270.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Dec;26(11-12):1465-77 [17900269.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Dec;293(6):G1106-13 [17932229.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2637-40 [18086768.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2649-55 [18086770.001]
  • [Cites] Gut. 2008 Feb;57(2):173-80 [17932103.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):174-80 [18386788.001]
  • [Cites] Am J Gastroenterol. 2008 May;103(5):1079-89 [18445097.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1169-78 [18483339.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4163-72 [18519675.001]
  • [Cites] Arch Iran Med. 2008 Jul;11(4):364-70 [18588366.001]
  • [Cites] Gut. 2008 Aug;57(8):1041-8 [18305067.001]
  • [Cites] Am J Epidemiol. 2008 Aug 1;168(3):237-49 [18550563.001]
  • [Cites] J Clin Gastroenterol. 2008 Aug;42(7):806-9 [18385604.001]
  • [Cites] Hum Pathol. 2008 Aug;39(8):1128-35 [18602665.001]
  • [Cites] Jpn J Clin Oncol. 2008 Jul;38(7):464-8 [18664481.001]
  • [Cites] Am J Gastroenterol. 2008 Jul;103(7):1614-23; quiz 1624 [18494834.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1184-7 [18695138.001]
  • [Cites] Genome Res. 2008 Sep;18(9):1518-29 [18577705.001]
  • [Cites] Mutagenesis. 2008 Sep;23(5):399-405 [18515815.001]
  • [Cites] BMC Genomics. 2008;9:394 [18717985.001]
  • [Cites] Gut. 2008 Oct;57(10):1354-9 [18424568.001]
  • [Cites] J Gastrointest Surg. 2008 Oct;12(10):1627-36; discussion 1636-7 [18704598.001]
  • [Cites] Dis Esophagus. 2008;21(6):529-38 [18840137.001]
  • [Cites] Mol Cancer. 2008;7:75 [18831746.001]
  • [Cites] Gastroenterology. 2008 Oct;135(4):1392-1413, 1413.e1-5 [18801365.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2008 Aug;22(4):659-69 [18971125.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):6988-95 [18980994.001]
  • [Cites] Gastrointest Endosc. 2008 Nov;68(5):849-55 [18547567.001]
  • [Cites] Contemp Clin Trials. 2009 Jan;30(1):2-7 [19013259.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Dec;23(12):1785-93 [19120871.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Oct;1(5):308-11 [19138974.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Oct;1(5):329-38 [19138977.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Nov;1(6):413-23 [19138988.001]
  • [Cites] Nat Genet. 2009 Feb;41(2):178-86 [19151715.001]
  • [Cites] Br J Cancer. 2009 Feb 10;100(3):551-7 [19156150.001]
  • [Cites] Am J Clin Nutr. 2009 Mar;89(3):890-6 [19144726.001]
  • [Cites] Cancer Causes Control. 2009 Apr;20(3):279-88 [18839322.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7629-33 [15492292.001]
  • [Cites] Nature. 1975 May 15;255(5505):197-200 [1143315.001]
  • [Cites] J Thorac Cardiovasc Surg. 1975 Nov;70(5):826-35 [1186274.001]
  • [Cites] Science. 1976 Oct 1;194(4260):23-8 [959840.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Gastroenterology. 1989 Feb;96(2 Pt 1):355-67 [2910757.001]
  • [Cites] Stat Med. 1989 Apr;8(4):431-40 [2727467.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Mar;105(3):383-7; discussion 387-8 [8445916.001]
  • [Cites] Stat Med. 1994 May 15;13(9):955-68 [8047747.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Nov;108(5):813-21; discussion 821-2 [7967662.001]
  • [Cites] Cancer Causes Control. 2009 Apr;20(3):303-11 [18853262.001]
  • [Cites] Gastroenterology. 2009 Mar;136(3):799-805 [19162028.001]
  • [Cites] Cell Cycle. 2009 Mar 15;8(6):809-17 [19229128.001]
  • [Cites] Gastroenterology. 2009 Apr;136(4):1215-24, e1-2 [19250648.001]
  • [Cites] Am J Gastroenterol. 2009 Apr;104(4):834-42 [19319131.001]
  • [Cites] Lancet. 2009 Apr 11;373(9671):1301-9 [19328542.001]
  • [Cites] Cancer Biomark. 2009;5(3):143-58 [19407369.001]
  • [Cites] Cancer Prev Res (Phila). 2009 May;2(5):459-65 [19401529.001]
  • [Cites] Histopathology. 2009 May;54(6):699-712 [19438745.001]
  • [Cites] Cancer Res. 2009 May 15;69(10):4112-5 [19435894.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):86-91 [9934736.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Gut. 1998 Aug;43(2):216-22 [10189847.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1837-9 [10213488.001]
  • [Cites] Nat Genet. 1999 May;22(1):106-9 [10319873.001]
  • [Cites] Gastroenterology. 1999 Aug;117(2):327-35 [10419913.001]
  • [Cites] Br J Surg. 1950 Oct;38(150):175-82 [14791960.001]
  • [Cites] Thorax. 1953 Jun;8(2):87-101 [13077502.001]
  • [Cites] Am J Gastroenterol. 2004 Nov;99(11):2107-14 [15554988.001]
  • [Cites] Semin Cancer Biol. 2005 Feb;15(1):51-60 [15613288.001]
  • [Cites] J Infect Dis. 2005 Mar 1;191(5):761-7 [15688293.001]
  • [Cites] Scand J Gastroenterol. 2004 Dec;39(12):1175-9 [15742992.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):771-8 [15765412.001]
  • [Cites] Am J Gastroenterol. 2005 Apr;100(4):775-83 [15784018.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2478-85 [15814623.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Apr;20(4):633-6 [15836715.001]
  • [Cites] JAMA. 2005 May 4;293(17):2095-101 [15870412.001]
  • [Cites] Cancer Causes Control. 2005 Apr;16(3):285-94 [15947880.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Jun;3(6):529-37 [15952094.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Jul;20(7):995-1001 [15955205.001]
  • [Cites] Ann Intern Med. 2005 Aug 2;143(3):199-211 [16061918.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2628-31 [16353151.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Mar 15;23(6):727-33 [16556174.001]
  • [Cites] Gastrointest Endosc. 2006 Apr;63(4):570-80 [16564854.001]
  • [Cites] Nat Genet. 2006 Apr;38(4):468-73 [16565718.001]
  • [Cites] JAMA. 2006 Apr 5;295(13):1549-55 [16595758.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4975-82 [16651456.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 May;4(5):566-72 [16630761.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):872-8 [16702363.001]
  • [Cites] J Natl Cancer Inst. 2006 Jun 7;98(11):748-56 [16757699.001]
  • [Cites] J Nutr. 2006 Jul;136(7 Suppl):1935S-1939S [16772463.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3661-97 [16778094.001]
  • [Cites] BMJ. 2006 Jun 24;332(7556):1512 [16793832.001]
  • [Cites] Scand J Gastroenterol. 2006 Aug;41(8):887-91 [16803686.001]
  • [Cites] Cancer Causes Control. 2006 Sep;17(7):901-9 [16841257.001]
  • [Cites] Cancer Causes Control. 2006 Sep;17(7):971-81 [16841264.001]
  • [Cites] Am J Gastroenterol. 2006 Jul;101(7):1430-6 [16863543.001]
  • [Cites] Aging Cell. 2006 Aug;5(4):325-30 [16913878.001]
  • [Cites] Carcinogenesis. 2006 Sep;27(9):1835-41 [16571649.001]
  • [Cites] Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943 [16928254.001]
  • [Cites] Anal Chem. 2006 Sep 1;78(17):5977-86 [16944874.001]
  • [Cites] Gut. 2006 Oct;55(10):1390-7 [16682429.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1668-73 [16985029.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1935-40 [17035402.001]
  • [Cites] Br J Surg. 2002 Jul;89(7):824-37 [12081731.001]
  • [Cites] Trends Biochem Sci. 2002 Jul;27(7):339-44 [12114022.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):745-52 [12163328.001]
  • [Cites] Gut. 2002 Sep;51(3):323-8 [12171951.001]
  • [Cites] Int J Cancer. 2002 Dec 20;102(6):551-5 [12447994.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):47-56 [12512029.001]
  • [Cites] Int J Cancer. 2003 May 20;105(1):98-100 [12672037.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1193-201 [12730860.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2560-6 [12855631.001]
  • [Cites] Lancet. 2005 Aug 20-26;366(9486):662-4 [16112303.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jun;46(6):532-42 [17330261.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1323-8 [17277236.001]
  • [Cites] Mol Cell Proteomics. 2007 Jun;6(6):987-99 [16829691.001]
  • [Cites] Genet Med. 2007 Jun;9(6):341-7 [17575500.001]
  • [Cites] Cancer Causes Control. 2007 Sep;18(7):713-22 [17562192.001]
  • [Cites] Transl Res. 2007 Jul;150(1):3-17 [17585859.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Jul;293(1):G264-70 [17431220.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):34-41; quiz 311 [17631128.001]
  • [Cites] J Mol Med (Berl). 2007 Jul;85(7):733-43 [17415542.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):403-11 [17681161.001]
  • [Cites] Carcinogenesis. 2005 Sep;26(9):1536-41 [15878910.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2151-6 [16181362.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):488-98 [16185958.001]
  • [Cites] Scand J Gastroenterol. 2005 Sep;40(9):1127-8 [16211720.001]
  • [Cites] Gastroenterology. 2005 Oct;129(4):1274-81 [16230080.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):945-52 [16321762.001]
  • [Cites] Am J Gastroenterol. 2005 Dec;100(12):2616-21 [16393209.001]
  • [Cites] J Urol. 2006 Feb;175(2):425-31 [16406965.001]
  • [Cites] Cancer Causes Control. 2000 Mar;11(3):231-8 [10782657.001]
  • [Cites] Aliment Pharmacol Ther. 2000 Apr;14 Suppl 1:3-9 [10807397.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1669-76 [10925966.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1316-21 [10944553.001]
  • [Cites] Am J Gastroenterol. 2000 Oct;95(10):2946-52 [11051373.001]
  • [Cites] Gut. 2001 Mar;48(3):304-9 [11171817.001]
  • [Cites] Ann Surg. 2001 Mar;233(3):322-37 [11224619.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):368-78 [11331953.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1355-62 [11374668.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1607-19 [11375943.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1630-9 [11375945.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • [Cites] Cancer Causes Control. 2001 Oct;12(8):721-32 [11562112.001]
  • [Cites] Am J Gastroenterol. 2001 Sep;96(9):2575-83 [11569678.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1055-62 [11588131.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):26-33 [11781277.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):55-9 [11781280.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):633-40 [11874995.001]
  • [Cites] Neoplasia. 2002 Mar-Apr;4(2):121-8 [11896567.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1101-12 [11910360.001]
  • [Cites] JAMA. 2002 Apr 17;287(15):1972-81 [11960540.001]
  • [Cites] Surg Endosc. 2002 Feb;16(2):263-6 [11967675.001]
  • [Cites] J Gastrointest Surg. 2002 Jan-Feb;6(1):29-35; discussion 36 [11986015.001]
  • [Cites] J Mol Diagn. 2008 Jan;10(1):67-77 [18083688.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):126-34 [18187391.001]
  • [Cites] Aliment Pharmacol Ther. 2008 Feb 15;27(4):316-20 [18062791.001]
  • [Cites] Cell Oncol. 2008;30(1):63-75 [18219111.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1303-10 [18000824.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):352-8 [18268119.001]
  • [Cites] Gut. 2008 Apr;57(4):448-54 [18178609.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):788-97 [18341497.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):727-31 [18349295.001]
  • [Cites] Gut. 2003 Aug;52(8):1081-4 [12865262.001]
  • [Cites] Gut. 2003 Aug;52(8):1085-9 [12865263.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):940-8 [12942560.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):695-701 [12951588.001]
  • [Cites] J Med Genet. 2003 Sep;40(9):651-6 [12960209.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13 [13130116.001]
  • [Cites] Am J Gastroenterol. 2003 Sep;98(9):1931-9 [14499768.001]
  • [Cites] Nature. 2004 Feb 26;427(6977):787 [14985739.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3414-27 [15150093.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):11-6 [15261138.001]
  • [Cites] Br J Surg. 2004 Aug;91(8):997-1003 [15286961.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):579-91 [15286738.001]
  • [Cites] Cancer Causes Control. 2004 Oct;15(8):837-43 [15456997.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Mar;4(2):85-92 [7742727.001]
  • [Cites] Am J Gastroenterol. 1996 Sep;91(9):1855-6 [8792715.001]
  • [Cites] Am J Gastroenterol. 1997 Apr;92(4):586-91 [9128304.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] Gastroenterology. 1997 Nov;113(5):1449-56 [9352846.001]
  • [Cites] Gut. 1997 Sep;41(3):303-7 [9378382.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):588-90 [9485003.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):97-102 [9488582.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1028-32 [9672324.001]
  • (PMID = 20094044.001).
  • [ISSN] 1474-1768
  • [Journal-full-title] Nature reviews. Cancer
  • [ISO-abbreviation] Nat. Rev. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA124911-02; United States / NCI NIH HHS / CA / K05 CA124911; United States / NCI NIH HHS / CA / P01 CA091955; United States / NCI NIH HHS / CA / P01 CA091955-08; United States / NCI NIH HHS / CA / K05 CA124911-02
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 218
  • [Other-IDs] NLM/ NIHMS200752; NLM/ PMC2879265
  •  go-up   go-down


82. Milano F, Guarriera M, Rygiel AM, Krishnadath KK: Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery. PLoS One; 2010 Aug 26;5(8):e12424
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery.
  • BACKGROUND: Esophageal adenocarcinoma (EAC) is a highly aggressive disease with poor prognosis, which frequently exhibits HER-2 gene amplification.
  • This enhances the ability of HER-2 specific cytotoxic T lymphocytes (CTLs) to recognize and kill cancer cells.
  • [MeSH-major] ATP-Binding Cassette Transporters / immunology. Adenocarcinoma / immunology. Antibodies, Monoclonal / pharmacology. Antigen Presentation / drug effects. Esophageal Neoplasms / immunology. Gene Expression / drug effects. Receptor, ErbB-2 / genetics. T-Lymphocytes / immunology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest Surg Clin N Am. 2000 Aug;10(3):441-50 [10967749.001]
  • [Cites] J Natl Cancer Inst. 2010 Feb 24;102(4):271-4 [20075370.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Int J Oncol. 2001 Dec;19(6):1211-20 [11713591.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8647-50 [11751378.001]
  • [Cites] Cancer Immunol Immunother. 2002 Jan;50(11):615-24 [11807625.001]
  • [Cites] Lancet Oncol. 2002 Mar;3(3):137-44 [11902499.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2244-7 [11956077.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):60-6 [12109857.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5813-7 [12384543.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3394-400 [12429626.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3407-18 [12429628.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3448-53 [12960136.001]
  • [Cites] World J Surg. 2003 Sep;27(9):999-1008; discussion 1006-8 [12917764.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):1-8 [15015764.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1063-70 [15020607.001]
  • [Cites] Ann Thorac Surg. 2004 Apr;77(4):1193-8; discussion 1198-9 [15063233.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2538-44 [15073134.001]
  • [Cites] Int J Oncol. 2004 Aug;25(2):487-91 [15254748.001]
  • [Cites] Ann Thorac Surg. 2004 Nov;78(5):1790-800 [15511476.001]
  • [Cites] Hum Pathol. 1993 Oct;24(10):1127-34 [8104858.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3353-7 [7724565.001]
  • [Cites] N Engl J Med. 1997 Jul 17;337(3):161-7 [9219702.001]
  • [Cites] Semin Oncol. 1999 Aug;26(4 Suppl 12):51-9 [10482194.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2552-60 [15814633.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4898-904 [16000588.001]
  • [Cites] Cancer Immunol Immunother. 2006 Jan;55(1):85-95 [15948002.001]
  • [Cites] J Immunother. 2006 Jan-Feb;29(1):53-60 [16365600.001]
  • [Cites] J Immunol. 2006 Mar 15;176(6):3402-9 [16517708.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5452-60 [16707474.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4925-32 [16914581.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):120-9 [17143264.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):405-9 [17097832.001]
  • [Cites] J Immunol Methods. 2007 Apr 10;321(1-2):94-106 [17336322.001]
  • [Cites] Cancer. 2007 May 15;109(10):1980-8 [17385213.001]
  • [Cites] Cancer Immunol Immunother. 2007 Dec;56(12):1967-77 [17564704.001]
  • [Cites] Cancer Immunol Immunother. 2008 Feb;57(2):197-206 [17622526.001]
  • [Cites] Cancer Immunol Immunother. 2008 Nov;57(11):1719-26 [18408926.001]
  • [Cites] Anal Cell Pathol. 2000;20(1):25-32 [11007435.001]
  • (PMID = 20865050.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ATP-Binding Cassette Transporters; 0 / ATP-Binding Cassette, Sub-Family B, Member 3; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 145892-13-3 / TAP2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  • [Other-IDs] NLM/ PMC2928738
  •  go-up   go-down


83. Lorenzo-Zúñiga V, Boix J: Endoscopic mucosal resection and mucosa ablation with argon-plasma coagulation in a high-risk patient with Barrett's oesophagus and oesophageal adenocarcinoma. Dig Liver Dis; 2006 Sep;38(9):713-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic mucosal resection and mucosa ablation with argon-plasma coagulation in a high-risk patient with Barrett's oesophagus and oesophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / surgery. Esophageal Neoplasms / surgery. Laser Coagulation. Mucous Membrane / surgery
  • [MeSH-minor] Aged. Argon. Esophagus / surgery. Humans. Male

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. Argon, Elemental .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16787771.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 67XQY1V3KH / Argon
  •  go-up   go-down


84. Vega KJ, Jamal MM, Wiggins CL: Changing pattern of esophageal cancer incidence in New Mexico: a 30-year evaluation. Dig Dis Sci; 2010 Jun;55(6):1622-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing pattern of esophageal cancer incidence in New Mexico: a 30-year evaluation.
  • BACKGROUND AND AIM: The incidence of esophageal adenocarcinoma has increased over the last 30 years, especially in non-Hispanic whites (nHw).
  • It is important to understand the effect of ethnicity on cancer occurrence over a prolonged interval.
  • METHODS: We searched the New Mexico Tumor Registry for all cases of esophageal cancer from 1 January 1973 to 31 December 2002.
  • Inclusion criteria were histologic diagnosis of adenocarcinoma or squamous cell carcinoma, ethnicity and gender.
  • Esophageal adenocarcinoma incidence rates/100,000 population increased significantly over 30 years; 1973-1977, 0.4 cases; 1978-1982, 0.4 cases; 1983-1987, 0.6 cases; 1988-1992, 1.2 cases, 1993-1997, 1.6 cases and 1998-2002, 2.2 cases; P < 0.001.
  • In nHw and HA, adenocarcinoma incidence rates increased significantly during the study period.
  • CONCLUSIONS: Esophageal adenocarcinoma incidence among nHw and HA increased from 1973 to 2002 in New Mexico.
  • Ethnicity may influence the histology or indicate an increased risk for certain types of esophageal cancer.
  • [MeSH-major] Adenocarcinoma / ethnology. Carcinoma, Squamous Cell / ethnology. Esophageal Neoplasms / ethnology. Ethnic Groups / statistics & numerical data

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Assoc Acad Minor Phys. 1999;10(2):44-7 [10826008.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):582-8 [15089886.001]
  • [Cites] N Engl J Med. 1985 Oct 3;313(14):857-9 [4033716.001]
  • [Cites] Gastroenterology. 1987 Jan;92(1):118-24 [3781178.001]
  • [Cites] Cancer. 1988 Feb 1;61(3):612-7 [3338027.001]
  • [Cites] Am J Gastroenterol. 1989 Dec;84(12):1494-6 [2596449.001]
  • [Cites] Br J Cancer. 1990 Sep;62(3):440-3 [2206952.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Arch Intern Med. 1991 Nov;151(11):2212-6 [1953225.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Endoscopy. 1995 Jan;27(1):19-26 [7601030.001]
  • [Cites] J Clin Gastroenterol. 1995 Oct;21(3):254-5 [8648065.001]
  • [Cites] Ann Clin Lab Sci. 1996 Nov-Dec;26(6):480-6 [8908317.001]
  • [Cites] J Clin Gastroenterol. 1998 Jan;26(1):11-3 [9492855.001]
  • [Cites] Dig Dis Sci. 1998 May;43(5):1038-41 [9590419.001]
  • [Cites] J Natl Med Assoc. 2005 Nov;97(11):1471-8 [16334494.001]
  • [Cites] Cancer Causes Control. 2007 Aug;18(6):585-93 [17406989.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Jan;6(1):30-4 [18063419.001]
  • [Cites] Am J Gastroenterol. 2000 Sep;95(9):2352-6 [11007241.001]
  • (PMID = 19688596.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2882567
  •  go-up   go-down


85. Quera R, O'Sullivan K, Quigley EM: Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma? Endoscopy; 2006 Feb;38(2):162-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?
  • BACKGROUND AND STUDY AIMS: The incidence of oesophageal adenocarcinoma has increased significantly in recent years.
  • While surveillance of people with Barrett's oesophagus, its usual precursor, has been advocated in order to detect dysplasia and early cancer in those considered to be at greatest risk, the impact of such a strategy on survival from oesophageal adenocarcinoma is unclear.
  • This study aimed to determine the effect of surveillance on mortality from oesophageal adenocarcinoma in a group of patients considered to be at high risk of developing Barrett's oesophagus and adenocarcinoma.
  • PATIENTS AND METHODS: After performing a Medline search of the literature published between 1985 and 2004 for studies on gastro-oesophageal reflux disease, Barrett's oesophagus and adenocarcinoma, we examined the impact of surveillance on mortality from oesophageal adenocarcinoma in a hypothetical sample of 100 high-risk patients (men aged over 50 with Barrett's oesophagus but without high-grade dysplasia at entry).
  • RESULTS: Four patients in this high-risk group developed adenocarcinoma during surveillance, with survival rates of 78.9% (95%CI 64.9%-88.5%) at 2 years and 78.6% (95%CI 62.8%-89.2%) at 5 years.
  • Meanwhile, between 515 and 2060 patients with Barrett's oesophagus were not detected or surveyed by this strategy and between 16 and 61 of these developed adenocarcinoma, with much lower survival rates of 37.1% (95%CI 25.4%-50.3%) at 2 years and 16.7% (95%CI 9%-28.3%) at 5 years.
  • Although surveillance in the high-risk group resulted in the long-term survival of three patients who would not otherwise have survived, this gain was dramatically offset by the 13 to 51 patients, excluded from surveillance by this strategy, who died from oesophageal adenocarcinoma.
  • CONCLUSIONS: A surveillance programme based on current concepts of risk cannot have an impact on mortality from oesophageal adenocarcinoma.
  • To be effective, it will be necessary for surveillance programmes to utilise more precise methods for the identification of those who are most at risk of progression to adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / mortality. Barrett Esophagus / epidemiology. Esophageal Neoplasms / mortality. Population Surveillance. Precancerous Conditions / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16479424.001).
  • [ISSN] 0013-726X
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


86. Bradbury PA, Zhai R, Hopkins J, Kulke MH, Heist RS, Singh S, Zhou W, Ma C, Xu W, Asomaning K, Ter-Minassian M, Wang Z, Su L, Christiani DC, Liu G: Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis. Carcinogenesis; 2009 May;30(5):793-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis.
  • We studied the association between four MMP polymorphisms within three MMP genes and esophageal adenocarcinoma (EA) risk and prognosis.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2002 Dec 10;102(5):526-9 [12432557.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2819-23 [12019159.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13 [13130116.001]
  • [Cites] Br J Cancer. 2003 Dec 1;89(11):2116-21 [14647147.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3b):2021-6 [15274394.001]
  • [Cites] J Biol Chem. 1996 May 31;271(22):13055-60 [8662692.001]
  • [Cites] Am J Gastroenterol. 1997 Feb;92(2):193-4 [9040189.001]
  • [Cites] J Pathol. 1998 Jul;185(3):256-61 [9771478.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5321-5 [9850057.001]
  • [Cites] Ann N Y Acad Sci. 1998 Oct 23;857:180-93 [9917841.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):481-6 [15528217.001]
  • [Cites] Breast Cancer Res. 2005;7(4):R506-12 [15987457.001]
  • [Cites] Carcinogenesis. 2006 May;27(5):1024-9 [16311244.001]
  • [Cites] World J Gastroenterol. 2007 Feb 7;13(5):676-82 [17278189.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1254-8 [17264068.001]
  • [Cites] BMC Cancer. 2007;7:187 [17919326.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3216-22 [18483390.001]
  • [Cites] Cancer Causes Control. 2008 Dec;19(10):1077-83 [18478337.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Circ Res. 2000 May 12;86(9):998-1003 [10807873.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Aug;15(8):1087-100 [11472311.001]
  • [Cites] Br J Cancer. 2001 Aug 3;85(3):383-92 [11487270.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7825-9 [11691799.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Apr 15;167(8):1083-9 [12522030.001]
  • (PMID = 19321798.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA074386
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.65 / Matrix Metalloproteinase 12; EC 3.4.24.7 / Matrix Metalloproteinase 1
  • [Other-IDs] NLM/ PMC2675656
  •  go-up   go-down


87. Dilemmas in managing Barrett's oesophagus. Drug Ther Bull; 2006 Sep;44(9):69-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dilemmas in managing Barrett's oesophagus.
  • In the UK, oesophageal adenocarcinoma accounts for over 7,000 deaths per year and its incidence is rising.
  • One risk factor for this cancer is Barrett's oesophagus.
  • Of people with Barrett's oesophagus, about 1% per year develop adenocarcinoma, around 30-125 times the rate in the general population.
  • So it has been suggested that people with reflux should be screened for Barrett's oesophagus, and those with the condition should be kept under surveillance to detect dysplasia or adenocarcinoma in the early stages.
  • Here we discuss the problems in managing patients with Barrett's oesophagus.
  • [MeSH-major] Barrett Esophagus / therapy

  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009567.001).
  • [ISSN] 0012-6543
  • [Journal-full-title] Drug and therapeutics bulletin
  • [ISO-abbreviation] Drug Ther Bull
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; R16CO5Y76E / Aspirin
  • [Number-of-references] 72
  •  go-up   go-down


88. Shirin H, Leja M, Niv Y: Helicobacter pylori and non-malignant diseases. Helicobacter; 2008 Oct;13 Suppl 1:23-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The main problems remain unsolved: peptic ulcer disease negative for H. pylori, synergism of H. pylori infection and aspirin and other nonsteroidal anti-inflammatory drugs or cyclooxygenase 2 specific inhibitors, the role of H. pylori eradication in uninvestigated and nonulcer dyspepsia, and the possible protective effect of H. pylori infection against gastroesophageal reflux disease and its complications such as Barrett's esophagus and adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18783518.001).
  • [ISSN] 1523-5378
  • [Journal-full-title] Helicobacter
  • [ISO-abbreviation] Helicobacter
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal
  •  go-up   go-down


89. Nair KS, Naidoo R, Chetty R: Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value. J Clin Pathol; 2005 Apr;58(4):343-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value.
  • Oesophageal carcinoma remains a disease of poor prognosis.
  • This review provides a brief description of five families of CAMs (cadherins, integrins, CD44, immunoglobulin superfamily, and selectins) and highlights their altered expression in relation both to prognosis and tumour behaviour in squamous cell carcinoma and adenocarcinoma of the oesophagus.
  • [MeSH-major] Cell Adhesion Molecules / analysis. Esophageal Neoplasms / chemistry
  • [MeSH-minor] Adenocarcinoma / chemistry. Antigens, CD44 / analysis. Cadherins / analysis. Carcinoma, Squamous Cell / chemistry. Humans. Integrins / analysis. Neoplasm Metastasis. Prognosis. Selectins / analysis